




# Programme

Wednesday 24 April 2013



# Modern management of rheumatoid arthritis

Is it a game of two halves?

Hall 5, ICC

Wednesday 24 April 2013 | 07:30–09:00

## Agenda

---

Welcome and introduction  
The current picture – a view from the clinic  
Exploring a changing landscape of therapeutic targets  
Panel discussion  
Exploring a changing imaging landscape  
Evolving needs in RA: understanding the full picture  
Panel discussion and audience Q&A

07:00–07:30 Light breakfast will be available

## Faculty

---

Dr Bruce Kirkman (Chair)  
*Consultant Rheumatologist,  
Guy's and St Thomas' NHS Foundation Trust*

Professor Peter Taylor  
*Consultant Rheumatologist,  
Kennedy Institute, Oxford*

Professor Philip Conaghan  
*Professor of Musculoskeletal Medicine,  
University of Leeds*

Dr Siegfried Wassenberg  
*Consultant Rheumatologist,  
Ev. Fachkrankenhaus, Ratingen, Germany*



# DIGITAL ULCERS AS A COMPLICATION OF SYSTEMIC SCLEROSIS.

REAL-WORLD CASE STUDIES: MANAGEMENT AND PREVENTION STRATEGIES AND THE IMPORTANCE OF MEASURING OUTCOMES

---

**Date:** Wednesday 24<sup>th</sup> April 2013

**Time:** 7.30am – 9.00am

**Location:** Hall 8

Breakfast will be provided from 7.00am

This symposium will provide attendees with the latest information on **management strategies** for digital ulcer patients and discuss the **importance of measuring outcomes** in treatment success.

## Chairs:

**Professor Christopher Denton**

University College London and Royal Free Hospital

**Professor Ariane Herrick**

University of Manchester and Salford Royal NHS Foundation Trust

## Expert panel discussing interactive case studies:

**Dr Frances Hall**

Addenbrooke's Hospital

**Dr Harsha Gunawardena**

North Bristol NHS Trust

**Dr Suzanne Donnelly**

Mater Misericordiae University Hospital

**Dr Colin Baines**

Ninewells Hospital, Dundee



Satellite symposium organised and sponsored by Actelion Pharmaceuticals UK Limited at the British Society for Rheumatology 2013 Conference.



07.00 – 07.30

Industry supported symposium catering

07.30 – 09.00

Industry supported symposium: Actelion | **Hall 8**

Digital ulcers as a complication of systemic sclerosis

Real-world case studies: management and prevention strategies and the importance of measuring outcomes

07.30


**Introduction to symposium, management and prevention strategies for SSc/DU patients and measuring outcomes**

*Prof Christopher Denton, University College London, London and Prof Ariane Herrick, University of Manchester, Manchester*

08.00

**Case studies and panel discussion**

*Dr Frances Hall, Addenbrooke's Hospital, Cambridge  
Dr Harsha Gunawardena, North Bristol NHS Trust, Bristol  
Dr Suzanne Donnelly, Mater Misericordiae University Hospital, Dublin  
Dr Colin Baines, Ninewells Hospital, Dundee*



# Modern management of rheumatoid arthritis

Is it a game of two halves?

Hall 5, ICC

Wednesday 24 April 2013 | 07:30–09:00

## Agenda

---

Welcome and introduction  
The current picture – a view from the clinic  
Exploring a changing landscape of therapeutic targets  
Panel discussion  
Exploring a changing imaging landscape  
Evolving needs in RA: understanding the full picture  
Panel discussion and audience Q&A

07:00–07:30 Light breakfast will be available

## Faculty

---

Dr Bruce Kirkman (Chair)  
*Consultant Rheumatologist,  
Guy's and St Thomas' NHS Foundation Trust*

Professor Peter Taylor  
*Consultant Rheumatologist,  
Kennedy Institute, Oxford*

Professor Philip Conaghan  
*Professor of Musculoskeletal Medicine,  
University of Leeds*

Dr Siegfried Wassenberg  
*Consultant Rheumatologist,  
Ev. Fachkrankenhaus, Ratingen, Germany*



07.00 – 07.30

Industry supported symposium catering

07.30 – 09.00

Industry supported symposium: Pfizer | Hall 5

Modern management of rheumatoid arthritis: is it a game of two halves?

Chair: Dr Bruce Kirkham, Guy's and St Thomas' NHS Foundation Trust

07.30

Welcome and introduction

Dr Bruce Kirkham, Guy's and St Thomas' NHS Foundation Trust, London

07.35

The current picture – a view from the clinic

Dr Bruce Kirkham, Guy's and St Thomas' NHS Foundation Trust, London

07.50

Exploring a changing landscape of therapeutic targets

Prof Peter Taylor, Kennedy Institute, Oxford

08.10

Panel discussion

08.20

Exploring a changing imaging landscape

Prof Philip Conaghan, University of Leeds, Leeds

08.30

Evolving needs in RA: understanding the full picture

Dr Siegfried Wassenberg, Ev. Fachkrankenhaus, Ratingen, Germany

08.45

Panel discussion and audience Q&A

09.00

Close

09.00 – 10.30

Essentials in rheumatology: Disease management | Hall 1

Chairs: Prof John Axford, London Rheumatology Clinic, London and Dr Charles Mackworth-Young, Imperial College London, London

Aim:

Outcome 1:

Outcome 2:

A comprehensive update covering everything you need to know about changes in rheumatology  
To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees  
Delegates will have been brought up to date on disease management

09.00

Recognition and management of the auto-inflammatory diseases

Prof Dennis McGonagle, University of Leeds, Leeds

09.30

Chronic fatigue syndrome and Fibromyalgia

Dr Frank McKenna, Central Manchester University Hospitals NHS Foundation Trust, Manchester

10.00

Sarcoidosis

Dr Toby Maher, Imperial College London, London

## 09.00 – 10.30

**Getting to grips with the use of social media tools in rheumatology | Hall 9**

*Chair: Dr Raj Sengupta, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath*

**Aim:**

To provide an overview of the potential use of new media to enhance communication in our practice of rheumatology

**Outcome 1:**

Delegates will be aware of the potential of social media to help clinicians improve communication with patients and colleagues including GPs and allied health professionals

**Outcome 2:**

Delegates will be aware of e-learning tools used to enhance education and know how they can contribute to the creation of educational material in new formats

**Outcome 3:**

Delegates will be aware of how to plan and manage their online 'presence', mindful of professional issues

09.00

**How to learn using social media technologies**

*Dr Ronan Kavanagh, Bon Secours Hospital, Galway, Ireland*

09.30

**Social media and academia**

*Dr Anne-Marie Cunningham, University of Cardiff, Cardiff*

10.00

**Connecting with charities and patients using social media**

*Ms Ruth Grosart, National Rheumatoid Arthritis Society (NRAS), Berkshire*

## 09.00 – 10.30

**Ultrasound: what is in it for you? | Hall 4**

*Chairs: Dr Zunaid Karim, Mid Yorkshire NHS Trust, Wakefield and Prof Peter Taylor, University of Oxford, Oxford*

**Aim:**

To provide rheumatologists with an outline of how using ultrasound can improve the care they offer to patients for each of the lecture

**Outcome 1:**

Delegates will be aware of the role ultrasound has played in improving the understanding and management of conditions discussed

**Outcome 2:**

Delegates will be able to recognise clinical situations where ultrasound is likely to benefit care

**Outcome 3:**

Delegates will have a better understanding of current and future ultrasound research with potential future role

09.00

**Ultrasound in rheumatoid arthritis**

*Dr Richard Wakefield, University of Leeds, Leeds*

09.30

**Ultrasound in spondyloarthropathy**

*Prof David Kane, Adelaide and Meath Hospital, Dublin, Ireland*

10.00

**Ultrasound in vasculitis**

*Prof Wolfgang Schmidt, Medical Centre for Rheumatology, Berlin, Germany*

## 09.00 – 10.30

**BHPR: Are our interventions cost-effective? | Hall 10**

*Chairs: Dr Martyn Lewis, Arthritis Research UK, Keele University, Keele and Dr Lindsay Bearn, King's College London, London*

**Aim:**

To provide an overview of health economics and cost-evaluation of interventions provided by health professionals in rheumatology

**Outcome 1:**

Delegates will be aware of basic concepts of health economics in the context of health and healthcare and how this influences policy

**Outcome 2:**

Delegates will have an increased awareness of the need for cost-evaluation of their interventions and the main types of cost-evaluation in healthcare

**Outcome 3:**

Delegates will have a greater understanding of how economic evaluation is undertaken by looking into cost-effectiveness studies in HPs interventions

09.00

**Considerations for health economics analysis in rheumatology**

*Dr Tracey Young, University of Sheffield, Sheffield*

09.30

**The cost-effectiveness of nurse-led care in people with RA**

*Dr Mwidimi Ndos, University of Leeds, Leeds*

09.55

**Cheap as chips and less fattening: economic evaluation of 'ESCAPE-pain' an integrated rehabilitation programme for chronic knee pain/OA**

*Prof Michael Hurley, St George's University of London and Kingston University, London*

## 09.00 – 10.30

**Managing the care gap: implementing evidence-based practice in primary care | Hall 11a**

*Chair: Dr Philip Helliwell, University of Leeds, Leeds*

**Aim:**

To highlight gaps between musculoskeletal research evidence and current primary care practice, updating delegates about the evidence and how the gaps can be addressed

**Outcome 1:**

Increased knowledge of what current best practice for osteoarthritis, back pain and osteoporosis in primary care should be

**Outcome 2:**

Understanding of how current clinical practice in primary care differs from the research evidence

**Outcome 3:**

Awareness of how rheumatologists and general practitioners can work together to address these gaps in care

09.00

**Osteoarthritis**

*Dr Mark Porcheret, Keele University, Keele*

09.30

**Mountains, pathways and surfing: implementing best practice for spinal pain**

*Dr Oliver Hart, Sheffield NHS, Sheffield*

10.00

**Falls and fractures in the frail elderly**

*Prof David Oliver, City University, London*



09.00 – 10.30

Oral abstracts: Adolescent and young adults | Hall 7

Chairs: Prof Lucy Wedderburn, University College London, London and Dr Janet McDonagh, University of Birmingham, Birmingham

09.00	<p><b>Hypermobility is a risk factor for musculoskeletal pain in adolescence: findings from a prospective cohort study</b></p> <p><i>Dr Jacqui Clinch, Bristol Royal Hospital for Children, Bath</i></p>
09.15	<p><b>The association between gastrointestinal symptoms and the joint hypermobility syndrome in a population of university students</b></p> <p><i>Dr Asma Fikree, Blizard Institute of Cell and Molecular Science, London</i></p>
09.30	<p><b>A comparison of the outcome of adolescent and adult onset systemic lupus erythematosus</b></p> <p><i>Dr Grainne Murphy, University College London, London</i></p>
09.45	<p><b>Anti-NXP2 autoantibody status is a predictor of calcinosis in older but not younger children who develop juvenile dermatomyositis</b></p> <p><i>Dr Sarah Tansley, Royal National Hospital for Rheumatic Diseases, Bath</i></p>
10.00	<p><b>Catch-up growth during Tocilizumab therapy for systemic juvenile idiopathic arthritis (SJIA): tender 2-year data</b></p> <p><i>Dr Eileen Baildam, Alder Hey Children's Hospital, Liverpool</i></p>
10.15	<p><b>Efficacy and safety of Tocilizumab in polyarticular juvenile idiopathic arthritis (PCJIA): CHERISH results at week 40</b></p> <p><i>Dr Athimalaipet Ramanan, Bristol Royal Hospital for Children and Royal National Hospital for Rheumatic Diseases, Bath</i></p>

09.00 – 10.30

SIG: Education | Executive Room 1

Chair: Prof Andrew Hassell, Haywood Hospital, Stoke-on-Trent and Keele University School of Medicine, Keele

<b>Aim:</b>	To promote the development of rheumatology education to patients and health professionals within rheumatology, to develop networks of rheumatology education, to develop collaborative research and development projects within rheumatology
<b>Outcome 1:</b>	For interested participants to progress a national project around the use and development of REMs in undergraduate medical education and to explore its potential in the education of rheumatology nurses and allied health professionals
<b>Outcome 2:</b>	To provide a forum for sharing and developing ideas in the field of education in rheumatology
<b>Outcome 3:</b>	For participants to receive an update on the work of Arthritis Research UK in this area, including discussion of the Educators' conference
09.00	<p><b>Development of a national evaluation of the Regional Evaluation of the Musculoskeletal System (REMS)</b></p> <p><i>Dr David Coady, City Hospital Sunderland Foundation Trust, Sunderland</i></p>
09.50	<p><b>An update on Arthritis Research UK education activities</b></p> <p><i>Dr Inam Haq, Arthritis Research UK and University of Brighton, Brighton and Mr Keir Windsor Arthritis Research UK, Chesterfield</i></p>

## 09.00 – 10.30

**IRS BHPR: Measuring disease activity in psoriatic arthritis | Hall 11b**

Places are limited to 36 attendees for this interactive workshop and will be allocated on a first come first served basis

*Chairs: Dr Michael Backhouse, University of Leeds, Leeds and Ms Kate Gadsby, Derby Hospitals Foundation Trust, Derby*

**Aim:**

To update delegates on current remission criteria and provide practical experience of disease activity scoring techniques

**Outcome 1:**

Understand importance of measuring disease activity in the context of modern disease management

**Outcome 2:**

Gain practical experience of performing joint assessments

09.00

**Measurement of disease activity in psoriatic arthritis and minimal disease activity**

*Dr Laura Coates, University of Leeds, Leeds*

09.20

**Assessing disease activity: instructions on aspects of minimal disease activity**

*Dr Laura Coates, University of Leeds, Leeds*

09.30

**Assessing disease activity workshop on minimal disease activity**

*Dr Laura Coates, University of Leeds, Leeds, Ms Victoria Chamberlain, Trafford Hospitals, Central Manchester University Hospitals Foundation NHS Trust, Manchester, Dr David Pickles, Chapel Allerton Hospital, Leeds and Ms Karen Partridge, Pennine MSK Partnership Ltd, Oldham*

10.00

**NAPSI: Nail psoriasis severity index**

*Dr David Pickles, Chapel Allerton Hospital, Leeds*

10.15

**Interactive quiz**

*Dr Michael Backhouse, University of Leeds, Leeds*

## 10:30 -11:30

**Rheumatology's open access options and compliance with funding bodies | Executive Room 1**

*Chair: Prof Robert Moots, Editor Rheumatology and University of Liverpool, Liverpool*

**Outcome 1:**

To discuss the open access options offered and compliance with funding bodies

**Outcome 2:**

Question and answer session

10:30

**Open access**

*Ms Julia McDonnell, Assistant Publisher, Oxford Journals, Oxford University Press, Oxford*

11:00

**Interactive Q&A session**

*Ms Julia McDonnell, Assistant Publisher, Oxford Journals, Oxford University Press, Oxford*

**Twitter**

@RheumatologyUK  
#Rheum2013

**LinkedIn Groups**

BSR  
Rheumatology 2013

**Facebook**

The British Society for  
Rheumatology

10.30 – 11.30

Poster viewing and exhibition | Tea and coffee

Categories

BHPR: Audit and clinical evaluation  
BHPR Research: qualitative  
BHPR Research: quantitative  
Biology of bone, cartilage and connective tissue disease  
Education  
Osteoporosis and metabolic bone disease  
Paediatric and adolescent rheumatology  
Pain  
Primary Care  
SLE and antiphospholipid syndrome

Poster Tours

BHPR  
SLE and antiphospholipid syndrome  
Education

10.30 – 11.00

NEW – Innovation theatre: Roche

Combination therapy in RA: Methotrexate debate  
*Prof Ernest Choy, University of Cardiff, Cardiff*

11.00 – 11.30

NEW – Innovation theatre: Medac

Early aggressive use of subcutaneous methotrexate – financial and health benefits  
*Dr Sandeep Bawa, Garthnavel General Hospital, Glasgow*

11.30 – 13.00

Essentials in rheumatology: Symptoms diagnosis and management | Hall 1

*Chairs: Prof John Axford, London Rheumatology Clinic, London and Dr Charles Mackworth-Young, Imperial College London, London*

Aim:  
Outcome 1:  
Outcome 2:

A comprehensive update covering everything you need to know about changes in rheumatology  
To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees  
Delegates will have had the opportunity to discuss symptom diagnosis

11.30

**Bursitis, enthesopathy and nerve entrapment**  
*Dr Andrew Keat, Northick Park Hospital, Harrow*

12.00

**Autoantibodies**  
*Prof Peter Maddison, Bangor University, Bangor*

12.30

**Improving patient management: Ready access to biological therapies**  
*Prof Peter Taylor, University of Oxford, Oxford and Prof Mark Baker, National Institute for Health and Clinical Excellence, Manchester*

**11.30 – 13.00****Arthritis pain: mechanisms, meaning and medicines | Hall 4***Chair: Prof David Walsh, University of Nottingham, Nottingham***Aim:**

To update on the current understanding of the pathophysiology and psychology of pain in people with arthritis, and recent advances in its medical management

**Outcome 1:**

Delegates will understand how the relationships between arthritis pain and joint pathology are complex, and how the way that we think about that relationship can have major impact on the development and use of effective analgesics

**Outcome 2:**

Clinical delegates will reflect on their own practice regarding what explanations they give patients of their pain, and how they should manage it

**Outcome 3:**

Delegates will be better able to offer advice about medications and exercise, and be aware of novel approaches that may better improve arthritis pain in the near future

11.30

**Pathophysiology of arthritis pain peripheral and spinal mechanisms of osteoarthritis pain: experimental models***Prof Victoria Chapman, University of Nottingham, Nottingham*

12.00

**Why does pain instil fear?***Prof Tamar Pincus, Royal Holloway, University of London, London*

12.30

**NGF inhibition as a strategy to treat musculoskeletal pain***Speaker to be announced***11.30 – 13.00****The emerging role of epigenetics in rheumatic diseases | Hall 5***Chairs: Prof Gerry Wilson, University of Sheffield, Sheffield and Prof Christopher Buckley, University of Birmingham, Birmingham***Aim:**

To provide an overview of the role of epigenetics in the pathogenesis of rheumatic diseases

**Outcome 1:**

To understand the epigenetic mechanisms controlling gene expression

**Outcome 2:**

To highlight current knowledge on the role of epigenetics in RA and OA

**Outcome 3:**

To be aware of the potential of therapeutic targeting of the epigenetic signature

11.30

**Epigenetic influences in autoimmune rheumatic diseases***Dr Esteban Ballestar, Chromatin and Disease Group, Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain*

12.00

**The epigenetic influences in osteoarthritis***Prof John Loughlin, Newcastle University, Newcastle*

12.30

**Therapeutic targeting of the epigenome***Dr Rabinder Prinjha, Immunoinflammation Therapy Area, GSK Medicines Research, Stevenage*

## 11.30 – 13.00

**BHPR plenary orals | Hall 10**

*Chairs: Prof James Woodburn, Glasgow Caledonian University, Glasgow and Mrs Lindsey Hawley, The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Christchurch*

- 11.30 **Clinical and cost-effectiveness of a multidisciplinary foot care programme for children and adolescents with juvenile idiopathic arthritis: an exploratory trial**  
*Dr Gordon Hendry, University of Western Sydney, Penrith, Australia*
- 11.45 **Predictors of risk of foot ulceration occurring in people with rheumatoid arthritis (RA) without diabetes**  
*Dr Jill Firth, Pennine Musculoskeletal Partnership, Oldham*
- 12.00 **“I’m being a better doctor”: training for clinicians to support self-management**  
*Dr Emma Dures, Bristol Royal Infirmary, Bristol*
- 12.15 **Widespread and regional pain predict social participation restriction in older adults: a prospective cohort study**  
*Dr Ross Wilkie, Keele University, Keele*
- 12.30 **Quality of life over the first 5-years of RA: findings from the early rheumatoid arthritis network**  
*Dr Sam Norton, King’s College London, London*
- 12.45 **Scottish Society of Rheumatology (SSR) occupational therapy rheumatoid arthritis (RA) work audit**  
*Mrs Katie McAlarey, Victoria Hospital, Glasgow*

## 11.30 – 13.00

**Oral abstracts: Primary care | Hall 7**

*Chairs: Dr Alan Nye, Pennine MSK Partnership Ltd, Oldham and Dr Peter Lanyon, Nottingham University Hospitals NHS Trust, Nottingham*

- 11.30 **Transcutaneous electrical nerve stimulation for the management of tennis elbow: a pragmatic randomized controlled trial**  
*Dr Linda Chesterton, Keele University, Keele*
- 11.45 **Gout is an independent risk factor for all types of vascular disease: a retrospective cohort study in the UK general practice research database (GPRD)**  
*Dr Lorna Clarkson, Keele University, Keele*
- 12.00 **Case-finding for osteoporosis and fracture in primary care**  
*Dr Jane Gibson, NHS Fife, Kirkcaldy*
- 12.15 **Development of a model consultation and training package for practice nurses to support self-management of patients consulting with osteoarthritis in primary care**  
*Dr Emma Healey, Keele University, Keele*
- 12.30 **Rocker sole shoes are no more beneficial than flat sole shoes in the management of chronic low back pain**  
*Dr Catherine Sian MacRae, King’s College London, London*
- 12.45 **The risk of a subsequent cancer diagnosis after PMR: a primary care database study**  
*Dr Sara Muller, Keele University, Keele*

## 11.30 – 13.00

**SIG: MSK disorders in ethnic minorities | Hall 8a***Chair: Prof Kuntal Chakravarty, Queen's Hospital, Essex*

**Aim:** To understand the metabolism and usefulness of Vitamin D in musculoskeletal disorders with emphasis on ethnic minorities

**Outcome 1:** To improve the understanding of vitamin D deficiency

**Outcome 2:** To improve the therapeutic challenges

**Outcome 3:** To develop research agendas

11.30 **Vitamin D: its effect in communities**

*Dr Michael Irani, Ashford Hospital, Middlesex*

12.00 **Why do ethnicity and diversity matter in MSK**

*Prof Mark Johnson, University of Leicester, Leicester*

12.30 **Vitamin D: when and how to replace**

*Dr Ashok Bhalla, Royal National Hospital for Rheumatic Disease NHS Foundation Trust, Bath*

## 11.30 – 13.00

**SIG: Adolescent and young adult rheumatology | Hall 11a**

*Chairs: Dr Alison Jordan, University Hospital Birmingham NHS Foundation Trust, Birmingham and Dr Liza McCann, Alder Hey Children's Hospital, Liverpool*

**Aim:** To update national clinical and academic picture in transitional rheumatology in key conditions that commence in childhood

**Outcome 1:** To gain updates in the increasing evidence supporting the transition of adolescents into adult services. Clinical and psychosocial outcomes

**Outcome 2:** To gain understanding in the different viewpoints clinically and academically of adolescent SLE from paediatric and adult experts

**Outcome 3:** To update on the pathophysiological understanding and clinical outcomes of adolescents and young adults with MAS/HLH

11.30 **Meeting at the edge: a paediatric and adult view of SLE in the adolescent years**

*Prof David Isenberg, University College London, London, and Prof Michael Beresford, Alder Hey Children's Hospital, Liverpool*

12.00 **Pathophysiology of teenage/young adult myositis: what have we learnt?**

*Prof Lucy Wedderburn, University College London, London*

12.20 **MAS/HLH: current understanding and management in adolescents and young adults**

*Dr Athimalaipet Ramanan, Bristol Royal Hospital for Children and Royal National Hospital for Rheumatic Diseases, Bath*

12.50 **Adolescent Rheumatology Research Network**

*Prof Lucy Wedderburn, University College London, London*



## 11.30 – 13.00

**SIG: Ultrasound | Hall 11b***Chair: Dr Zunaid Karim, Mid Yorkshire NHS Trust, Wakefield***Aim:**

To allow for those around the UK with a specialist interest in ultrasound to meet and update each other with regards to training programmes for ultrasound, course development and registrar training needs in ultrasound

**Outcome 1:**

Delegates will be aware of new developments in BSR ultrasound courses, where they will be held and the agreed outline for future courses

**Outcome 2:**

Delegates will be informed of results of a questionnaire of rheumatology trainees' thoughts on ultrasound training requirements

**Outcome 3:**

Delegates will have update from specific training programmes in other European Countries

11.30

**StRs perspective on ultrasound training needs, food for thought***Dr Rainer Klocke, Dudley NHS Foundation Trust, Dudley*

11.50

**Ultrasound training programmes, what's new?***Dr Zunaid Karim, Mid Yorkshire NHS Trust, Wakefield*

12.10

**Online learning and ultrasound injection course***Dr David Wright, City Hospitals Sunderland NHS Foundation Trust, Sunderland*

12.30

**Ultrasound training in Europe: lessons to be learnt***Dr Cristina Estrach, University Aintree Hospital NHS Foundation Trust, Liverpool***BSR AGM | Hall 9**

Wednesday 24 April | 13.00 – 14.15

Please join your colleagues and meet the Trustees, Regional Chairs and committee members of your Society. Hear what they have been doing on your behalf including the planned integration with BHPR and how they plan to meet the challenges of the year ahead.

Your attendance is highly valued.  
Lunch will be provided.

13.00 – 14.30

Exhibition | Lunch

13.00 – 14.15

**BSR AGM | Hall 9**

Please join your colleagues and meet the Trustees, Regional Chairs and committee members of your Society. Hear what they have been doing on your behalf including the planned integration with BHPR and how they plan to meet the challenges of the year ahead. Your attendance is highly valued and tasty lunch bags will be provided.

14.30 – 16.00

**IRS Essentials in rheumatology: Clinical decision making | Hall 1**

*Chairs: Prof John Axford, St George's University of London, London and Dr Charles Mackworth-Young, Imperial College London, London*

**Aim:**  
**Outcome 1:**  
**Outcome 2:**

A comprehensive update covering everything you need to know about changes in rheumatology  
To prepare rheumatologists for revalidation and provide a valuable educational opportunity for trainees  
Delegates will have had their clinical decision making skills tested

14.30

**Pregnancy: lessons learnt from miscarriage and foetal loss**

*Prof Lesley Regan, Imperial College London, London*

15.15

**Lupus**

*Dr David D'Cruz, St Thomas' Hospital, London*

14.30 – 16.00

**BSR/BHPR: Longstanding musculoskeletal pain: impact, perceptual representations and treatment  
Hall 11a**

*Dr Nicholas Shenker, Cambridge University Hospitals, Cambridge and Dr Melanie Holden, Arthritis Research UK, Keele University, Keele*

**Aim:**  
**Outcome 1:**  
**Outcome 2:**  
**Outcome 3:**

To provide delegates with an understanding of how long-standing musculoskeletal pain affects both society and the individual and learn how novel approaches have exciting potential in rheumatology  
Recognise societal impact and disease burden of long-standing musculoskeletal pain  
Understand how the perceptual representation of the body in pain can impact on function, and how this can be manipulated for therapeutic effect  
Understand the principles of graded exposure therapy (a psychological/functional approach) and how it may be clinically effective in treating pain

14.30

**Musculoskeletal pain: the societal burden**

*Dr Gareth Jones, University of Aberdeen, Aberdeen*

15.00

**Perceptions of the painful body in function**

*Dr Jenny Lewis, Royal National Hospital for Rheumatic Disease NHS Foundation Trusts, Bath*

15.30

**Graded exposure in vivo for CRPS-I**

*Dr Marlies den Hollander, Maastricht University, Maastricht, The Netherlands*

## 14.30 – 16.00

**Adolescent and young adult rheumatology | Hall 10**

*Chairs: Dr Rachel Tattersall, Royal Hallamshire Hospital, Sheffield and Prof Lucy Wedderburn, University College London, London*

**Aim:**

To provide adult rheumatologists and health professionals who care for young adults and/or adolescents with child onset rheumatological conditions with an overview of current best practice in key areas

**Outcome 1:**

Delegates will have an update on current understanding evidence based on optimal therapeutic management and outcomes of young adults who have arthritis that commenced in childhood

**Outcome 2:**

Delegates will gain insight into psychosocial impact of JIA on the adolescent and parent and current practice on how to use this knowledge to improve outcomes

**Outcome 3:**

Delegates will gain updated knowledge concerning the clinical approach of treating adolescents and young adults with childhood onset myositis

14.30

**Young adults with child onset arthritis: how our current understanding of the disease and management affect physical and psychosocial outcomes**

*Dr John Ioannou, University College Hospital, London*

14.50

**Psychosocial challenges of teenagers/young adults with JIA: can adolescents/young adults be persuaded to 'take the medicine'?**

*Dr Janet McDonagh, University of Birmingham, Birmingham*

15.10

**Psychosocial challenges of teenagers/young adults with JIA: direct and indirect effect of parenting behaviour on older teenagers with JIA – help or hindrance?**

*Dr Jacqui Clinch, Bristol Royal Hospital for Children, Bath*

15.30

**How to manage adolescent onset myositis in teenagers and young adults**

*Dr Clarissa Pilkington, Great Ormond Street Hospital, London*

## 14.30 – 16.00

**BHPR: Clinical update on axial spondyloarthritis (ASpA) | Hall 4**

*Chairs: Mrs Susan Gurden, St Woolos Hospital, Newport and Ms Lindsey Hooper, University of Southampton, Southampton*

**Aim:**

To provide an overview on current thinking on classification of Inflammatory back pain, recognition, assessment and implementation of treatment, monitoring and management strategies

**Outcome 1:**

To discuss issues and uncertainties in diagnostic recognition and onward management of inflammatory back pain

**Outcome 2:**

To highlight the implications of psychological status on subjective assessments and awareness of the importance of inter and intra operator reliability when completing BASMI assessment

**Outcome 3:**

To introduce the concept and implementation of negotiated monitoring and management strategies, to raise awareness and understanding of specific patient needs within the multidisciplinary team

14.30

**Advances in the diagnosis and management of 'Axial SpA'**

*Dr Stefan Siebert, Princess of Wales Hospital, Glasgow*

15.00

**Current assessment in ankylosing spondylitis and the importance of a biopsychosocial approach**

*Dr Jane Martindale, Wrightington, Wigan and Leigh NHS Foundation Trust, Lancashire*

15.30

**Ankylosing spondylitis individual personal care plan**

*Mr Colin Beevor, Queen Alexandra Hospital, Portsmouth and Ms Claire Jeffries, Queen Alexandra Hospital, Cosham*

14.30 – 16.00

Oral abstracts: OA and metabolic bone disease | Hall 8b

Chairs: Dr Tonia Vincent, Kennedy Institute of Rheumatology, London and Dr Ken Poole, University of Cambridge, Cambridge

14.30	<b>Maternal milk intake is associated with increased offspring bone mineral content</b> <i>Dr Zoe Cole, MRC Lifecourse Epidemiology Unit, Southampton</i>
14.45	<b>Bisphosphonate use and improved implant survival: a nation-wide cohort study</b> <i>Dr Daniel Prieto-Alhambra, Green Templeton College, Oxford</i>
15.00	<b>Mortality following elective total hip replacement and hip resurfacing</b> <i>Dr Adrian Kendal, University of Oxford, Oxford</i>
15.15	<b>Effect of strontium ranelate on knee pain in osteoarthritis: a responder analysis</b> <i>Prof Cyrus Cooper, University of Southampton, Southampton</i>
15.30	<b>Predictors of poor long-term outcome in physical function following TKA</b> <i>Dr Amit Kiran, University of Oxford, Oxford</i>
15.45	<b>Pegloticase for refractory gout: efficacy and safety summary of the GOUT1 and GOUT2 phase 3 trials</b> <i>Dr Faith Ottery, Savient Pharmaceuticals, Inc. New York, USA</i>

14.30 – 16.00

ARMA: Musculoskeletal clinical networks in the new NHS landscape | Hall 7

Chair: Mr Federico Moscogiuri, ARMA, London

<b>Aim:</b>	Discuss and identify ways to ensure that MSK services reflect local population needs via the development of MSK clinical networks
<b>Outcome 1:</b>	Present and ‘test out’ work done by ARMA on clinical networks to date via its strategic partnership with the DH
<b>Outcome 2:</b>	Identify key challenges in establishing and supporting effective MSK clinical networks
<b>Outcome 3:</b>	Identify examples of existing good practice and means of disseminating this with key stakeholders and call to action
14.30	<b>Introduction</b> <i>Mr Federico Moscogiuri, ARMA, London</i>
14.40	<b>The state of musculoskeletal disorders (MSDs) in the NHS</b> <i>Dr Chris Deighton, Derby Hospitals NHS Foundation Trust, Derby</i>
14.55	<b>Making it happen: how clinical networks can provide a solution</b> <i>Dr Alan Nye, Pennine MSK Partnership Ltd, Oldham</i>
15.10	<b>Challenges faced by patients living with a musculoskeletal disorder and clinical networks</b> <i>Ms Debbie Cook, CEO NASS – National Ankylosing Spondylitis Society, Surrey</i>
15.25	<b>Interactive panel discussion with question and answer session</b> <i>Mr Federico Moscogiuri, ARMA, London</i>

14.30 – 16.00

SIG: SLE | Hall 8a

Chair: Prof Ian Bruce, University of Manchester, Manchester

- Aim:**

**Outcome 1:**

**Outcome 2:**

**Outcome 3:**
- To learn about the range of neuropsychiatric manifestations associated with SLE and consider how to develop a differential diagnosis and management plan for such patients

To understand the range of neuropsychiatric manifestations in SLE

To develop a strategy to investigate neuropsychiatric manifestations in SLE patients as well as stroke syndromes in younger adults

To learn about management options in patients across the range of neuropsychiatric manifestations in SLE
- 14.30

14.50

15.15

15.35
- An overview of the clinical presentation and manifestations of neuropsychiatric lupus: a rheumatologist’s viewpoint**

*Prof Caroline Gordon, University of Birmingham, Birmingham*

**Assessment of neuropsychiatric manifestations of SLE: a neurologist’s view point**

*Dr Michael Zandi, University of Cambridge, Cambridge*

**General assessment and management of stroke syndromes in younger adults: a stroke specialist’s viewpoint**

*Dr Ganesh Subramanian, Nottingham University Hospital, Nottingham*

**EULAR guidelines on the management of neuropsychiatric manifestations of SLE: a task force’s viewpoint**

*Dr George Bertias, University of Crete, Greece*

14.30 – 16.00

IRS BHPR: Measuring disease activity in RA, when is your patient in remission | Hall 11b

Places are limited to 36 attendees for this interactive workshop and will be allocated on a first come first served basis

Chair: Dr Michael Backhouse, University of Leeds, Leeds

- Aim:** To update delegates on current remission criteria and provide practical experience of disease activity scoring techniques
- Outcome 1:** Understand importance of measuring disease activity in the context of modern disease management
- Outcome 2:** Gain practical experience of performing joint assessments
- Outcome3:** Update on role of imaging in assessing disease activity

14.30 Why measure disease activity and what should we aim to achieve?

Prof Peter Taylor, University of Oxford, Oxford

14.50 Assessing disease activity: workshop instructions on DAS Scoring

Dr Jill Firth, Pennine Musculoskeletal Partnership, Oldham

15.00 Assessing disease activity in RA

Dr Jill Firth, Pennine Musculoskeletal Partnership, Oldham, Ms Victoria Chamberlain, Trafford Hospitals, Central Manchester University Hospitals Foundation NHS Trust, Manchester and Dr David Pickles, Chapel Allerton Hospital, Leeds

15.30 The role of imaging in assessing disease activity

Prof Peter Taylor, University of Oxford, Oxford

15.45 Interactive quiz

Dr Michael Backhouse, University of Leeds, Leeds

16.00 – 16.30

Exhibition | Tea and coffee

16.30 – 17.30

Heberden Oration | Hall 1

The changing face of rheumatoid arthritis: a palindromic shift

Prof Paul Emery, University of Leeds, Leeds



17.30 – 17.45

Industry supported symposium catering

17.45 – 19.15

Industry supported symposium: AbbVie | Hall 5

Introducing a Targeted Ultrasound Initiative: New Standards for Assessment in RA

*Chair: Prof Paul Emery University of Leeds, Leeds*

Lecture 1:

Taking T2T to the next level

*Prof Paul Emery, University of Leeds, Leeds*

Lecture 2:

Ultrasound in practice

*Dr Zunaid Karim, Mid Yorkshire NHS Trust, Wakefield*

Lecture 3:

Targeted Ultrasound Initiative (TUI) in the UK

*Dr Cristina Estrach, University Aintree Hospital NHS Foundation Trust, Liverpool*

Lecture 4:

The role of the Nurse Specialist in ultrasound

*Mrs Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole*

19.30 – Late

**Conference Dinner**

With a lively and diverse culture, Birmingham has a never ending offering of delicious restaurants to try, none better than the popular Shimla Pinks. BSR and BHPR invites guests to carry on networking into the night at this award winning restaurant. Enjoy!



- Promoting Ultrasound
- Applying Ultrasound
- Improving Outcomes



---

# INTRODUCING A TARGETED ULTRASOUND INITIATIVE: NEW STANDARDS FOR ASSESSMENT IN RA

---

**Date:** Wednesday 24<sup>th</sup> April 2013  
**Time:** 17.30-19.15  
**Where:** Hall 5, Birmingham ICC

---

## AGENDA

Chaired by Professor Paul Emery

---

**Taking T2T to The Next Level**  
Professor Paul Emery

---

**US in Practice**  
Dr Zunaid Karim

---

**TUI in the UK**  
Dr Cristina Estrach

---

**Role of Nurse Specialist**  
Tricia Cornell

---

**abbvie**

Prescribing information will be available at this meeting

Sponsored by AbbVie. Date of Preparation March 2013. AXHUR130290a (1)

TUI is an educational programme initiated by the TUI Group, AbbVie and GE Healthcare and supported, additionally, by Patient Central. AbbVie and GE Healthcare provide financial support for programme and Patient Central serves in the role of programme director to provide strategic direction and the co-ordination and delivery of its activities according to objectives set by the TUI Group and under its direction. Unless otherwise stated, the medical and scientific content of TUI reflects the knowledge and opinions of the named experts, who determine, independently, and approve the final content of all aspects of the TUI programme

**ADOLESCENT AND YOUNG ADULT 09.00-10.30**

- O13 HYPERMOBILITY IS A RISK FACTOR FOR MUSCULOSKELETAL PAIN IN ADOLESCENCE: FINDINGS FROM A PROSPECTIVE COHORT STUDY**  
Jon Tobias<sup>1</sup>, Kevin Deere<sup>1</sup>, Shea Palmer<sup>2</sup>, Emma Clark<sup>1</sup>, Jacqui Clinch<sup>3</sup>  
<sup>1</sup>Musculoskeletal Research Unit, University of Bristol, Bristol, United Kingdom; <sup>2</sup>Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom; <sup>3</sup>Paediatric Rheumatology, Bristol Royal Hospital for Children, Bristol, United Kingdom
- O14 THE ASSOCIATION BETWEEN GASTROINTESTINAL SYMPTOMS AND THE JOINT HYPERMOBILITY SYNDROME IN A POPULATION OF UNIVERSITY STUDENTS**  
Asma Fikree<sup>1</sup>, Rubina Aktar<sup>1</sup>, Georgina Wellstead<sup>1</sup>, Charles Knowles<sup>2</sup>, Rodney Grahame<sup>3</sup>, Qasim Aziz<sup>1</sup>  
<sup>1</sup>Neurogastroenterology, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom; <sup>2</sup>National Centre for Bowel Research and Surgical Innovation, Blizard Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, United Kingdom; <sup>3</sup>Rheumatology, University College Hospital, London, United Kingdom
- O15 A COMPARISON OF THE OUTCOME OF ADOLESCENT- AND ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS**  
Beatriz Amaral<sup>1</sup>, Grainne Murphy<sup>1</sup>, Yiannis Ioannou<sup>1</sup>, David A. Isenberg<sup>1</sup>  
<sup>1</sup>Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom

- O16 ANTI-NXP2 AUTOANTIBODY STATUS IS A PREDICTOR OF CALCINOSIS IN OLDER BUT NOT YOUNGER CHILDREN WHO DEVELOP JUVENILE DERMATOMYOSITIS**  
Sarah L. Tansley<sup>1</sup>, Zoe E. Betteridge<sup>2</sup>, Harsha Gunawardena<sup>3</sup>, Gavin Shaddick<sup>4</sup>, Hemlata Varsani<sup>5</sup>, Lucy Wedderburn<sup>5</sup>, Neil McHugh<sup>1,2</sup>  
<sup>1</sup>Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; <sup>2</sup>Research, Bath Institute of Rheumatic Diseases, Bath, United Kingdom; <sup>3</sup>Rheumatology, North Bristol NHS trust, Bristol, United Kingdom; <sup>4</sup>Mathematics, University of Bath, Bath, United Kingdom; <sup>5</sup>Rheumatology, Institute of Child Health, London, United Kingdom
- O17 CATCH-UP GROWTH DURING TOCILIZUMAB THERAPY FOR SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: TENDER 2-YEAR DATA**  
Fabrizio De Benedetti<sup>1</sup>, Nicolino Ruperto<sup>2</sup>, Graciela Espada<sup>2</sup>, Valeria Gerloni<sup>2</sup>, Berit Flato<sup>2</sup>, Gerd Horneff<sup>3</sup>, Barry L. Myones<sup>4</sup>, Karen Onel<sup>4</sup>, James Frane<sup>5</sup>, Andrew Kenwright<sup>6</sup>, Terri H. Lipman<sup>7</sup>, Kamal N. Bharucha<sup>5</sup>, Alberto Martini<sup>2</sup>, Daniel J. Lovell<sup>4</sup>  
<sup>1</sup>Rheumatology, Ospedale Pediatrico Bambino Gesù, Rome, Italy; <sup>2</sup>Paediatric Rheumatology, Paediatric Rheumatology International Trials Organisation-IRCCS [PRINTO], Genoa, Italy; <sup>3</sup>Paediatric Rheumatology, Centre of Paediatric Rheumatology, Sankt Augustin, Germany; <sup>4</sup>Paediatric Rheumatology, Pediatric Rheumatology Collaborative Study Group [PRCSG], Cincinnati, OH, USA; <sup>5</sup>Medical, Genentech, South San Francisco, CA, USA; <sup>6</sup>Medical, Roche Products Ltd, Welwyn Garden City, United Kingdom; <sup>7</sup>Nursing of Children, University of Pennsylvania School of Nursing, Philadelphia, PA, USA

**018 EFFICACY AND SAFETY OF TOCILIZUMAB IN POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS: CHERISH RESULTS AT WEEK 40**

Eileen Baildam<sup>1</sup>, Nicolino Ruperto<sup>2</sup>, Hermine Brunner<sup>3</sup>, Zbigniew Zuber<sup>2</sup>, Caroline Keane<sup>4</sup>, Olivier Harari<sup>4</sup>, Andrew Kenwright<sup>4</sup>, Ruben J. Cuttica<sup>2</sup>, Vladimir Keltsev<sup>2</sup>, Ricardo Xavier<sup>2</sup>, Inmaculada C. Penades<sup>2</sup>, Irina Nikishina<sup>5</sup>, Nadina Rubio-Perez<sup>2</sup>, Ekaterina Alekseeva<sup>2</sup>, Vyacheslav Chasnyk<sup>6</sup>, Jose Chavez<sup>2</sup>, Gerd Horneff<sup>7</sup>, Violetta Opoka-Winiarska<sup>2</sup>, Pierre Quartier<sup>8</sup>, Clovis A. Silva<sup>2</sup>, Earl D. Silverman<sup>3</sup>, Alberto Spindler<sup>3</sup>, Daniel J. Lovell<sup>3</sup>, Alberto Martini<sup>2</sup>, Fabrizio De Benedetti<sup>9</sup>

<sup>1</sup>Paediatric Rheumatology, Royal Liverpool Children's Hospital, Liverpool, United Kingdom; <sup>2</sup>Paediatric Rheumatology, Paediatric Rheumatology International Trials Organisation-IRCCS [PRINTO], Genoa, Italy; <sup>3</sup>Paediatric Rheumatology, Pediatric Rheumatology Collaborative Study Group [PRCSG], Cincinnati, OH, USA; <sup>4</sup>Medical, Roche Products Ltd, Welwyn Garden City, United Kingdom; <sup>5</sup>Rheumatology, Scientific Research Institute of Rheumatology RAMS, Moscow, Russian Federation; <sup>6</sup>Rheumatology, International Investigator Consortium for MAS Diagnostic Criteria, Moscow, Russian Federation; <sup>7</sup>Paediatric Rheumatology, Centre of Paediatric Rheumatology, Sankt Augustin, Germany; <sup>8</sup>Rheumatology, Necker-Enfants Malades Hospital, Paris, France; <sup>9</sup>Paediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy

**BHPR PLENARY ORALS**

**11.30-13.00**

**019 CLINICAL AND COST EFFECTIVENESS OF A MULTIDISCIPLINARY FOOT CARE PROGRAM FOR CHILDREN AND ADOLESCENTS WITH JUVENILE IDIOPATHIC ARTHRITIS: AN EXPLORATORY TRIAL**

Gordon J. Hendry<sup>1,2</sup>, Gordon F. Watt<sup>1</sup>, Mhairi Brandon<sup>3</sup>, Lorraine Friel<sup>3</sup>, Deborah Turner<sup>1</sup>, Paula K. Lorgelly<sup>4</sup>, Janet Gardner-Medwin<sup>5</sup>, Roger D. Sturrock<sup>6</sup>, James Woodburn<sup>1</sup>

<sup>1</sup>Institute for Applied Health Research, Glasgow Caledonian University, Glasgow, United Kingdom; <sup>2</sup>School of Science and Health, University of Western Sydney, Penrith, NSW, Australia; <sup>3</sup>Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom; <sup>4</sup>Centre for Health Economics, Monash University, Clayton, NSW, Australia; <sup>5</sup>Department of Child Health, University of Glasgow, Glasgow, United Kingdom; <sup>6</sup>Centre for Rheumatic Diseases, University of Glasgow, Glasgow, United Kingdom

**020 PREDICTORS OF RISK OF FOOT ULCERATION OCCURRING IN PEOPLE WITH RHEUMATOID ARTHRITIS WITHOUT DIABETES**

Jill Firth<sup>1</sup>, Robin Waxman<sup>2</sup>, Graham Law<sup>3</sup>, Heidi Siddle<sup>2</sup>, Andrea E. Nelson<sup>1</sup>, Philip Helliwell<sup>2</sup>, Simon Otter<sup>4</sup>, Violet Butters<sup>5</sup>, Lorraine Loughrey<sup>2</sup>, Begonya Alcacer-Pitarch<sup>2</sup>, Jennifer Tranter<sup>6</sup>, Samantha Davies<sup>7</sup>, Rosemary Hryniw<sup>8</sup>, Sarah Lewis<sup>9</sup>, Lesley Baker<sup>4</sup>

<sup>1</sup>School of Healthcare, University of Leeds, Leeds, United Kingdom; <sup>2</sup>Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; <sup>3</sup>Biostatistics Unit, University of Leeds, Leeds, United Kingdom; <sup>4</sup>Division of Podiatry, University of Brighton, Brighton, United Kingdom; <sup>5</sup>Podiatry Department, Greater Glasgow and Clyde NHS Trust, Glasgow, United Kingdom; <sup>6</sup>Division of Primary Care, University of Nottingham, Nottingham, United Kingdom; <sup>7</sup>Podiatry Department, Pennine Acute Hospitals NHS Trust, Oldham, United Kingdom; <sup>8</sup>Podiatry Department, University Hospitals of Morecambe NHS Trust, Morecambe, United Kingdom; <sup>9</sup>Podiatry Department, Calderdale and Huddersfield NHS Foundation Trust, Huddersfield, United Kingdom

**021 "I'M BEING A BETTER DOCTOR": TRAINING FOR CLINICIANS TO SUPPORT SELF-MANAGEMENT**

Emma Dures<sup>1</sup>, Sarah Hewlett<sup>1</sup>, Nicholas Ambler<sup>2</sup>, Joyce Clarke<sup>3</sup>, Rachael Gooberman-Hill<sup>4</sup>, Remona Jenkins<sup>3</sup>

<sup>1</sup>Academic Rheumatology, University of the West of England, Bristol, United Kingdom; <sup>2</sup>Pain Management Centre, Frenchay Hospital, Bristol, United Kingdom; <sup>3</sup>Academic Rheumatology, University of Bristol, Bristol, United Kingdom; <sup>4</sup>Orthopaedic Surgery Research Group, University of Bristol, Bristol, United Kingdom

**022 WIDESPREAD AND REGIONAL PAIN PREDICT SOCIAL PARTICIPATION RESTRICTION IN OLDER ADULTS: A PROSPECTIVE COHORT STUDY**

Ross Wilkie<sup>1</sup>, Milisa Bucknall<sup>1</sup>, Kelvin Jordan<sup>1</sup>, John McBeth<sup>1</sup>

<sup>1</sup>Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom

**023 QUALITY OF LIFE OVER THE FIRST 5 YEARS OF RA: FINDINGS FROM THE EARLY RHEUMATOID ARTHRITIS NETWORK**

Sam Norton<sup>1</sup>, David Walsh<sup>2</sup>, Patrick Kiely<sup>3</sup>, Richard Williams<sup>4</sup>, Adam Young<sup>5</sup>

<sup>1</sup>Psychology Department, King's College London, London, United Kingdom; <sup>2</sup>Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom; <sup>3</sup>Rheumatology, St George's Healthcare NHS Trust, London, United Kingdom; <sup>4</sup>Rheumatology, Hereford Hospitals NHS Trust, Hereford, United Kingdom; <sup>5</sup>Rheumatology, West Hertfordshire Hospitals NHS Trust, St Albans, United Kingdom



**BHPR clinical prize award winner**

**024 SCOTTISH SOCIETY OF RHEUMATOLOGY OCCUPATIONAL THERAPY RHEUMATOID ARTHRITIS WORK AUDIT**

Janet E. Harkess<sup>1</sup>, Katie McAleary<sup>2</sup>

<sup>1</sup>Occupational Therapy Department, Fife Rheumatic Diseases Unit, Kirkcaldy, United Kingdom; <sup>2</sup>Occupational Therapy Department, New Victoria Hospital, Glasgow, United Kingdom

**PRIMARY CARE**

**11.30-13.00**

**025 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION FOR THE MANAGEMENT OF TENNIS ELBOW: A PRAGMATIC RANDOMIZED CONTROLLED TRIAL**

Linda Chesterton<sup>1</sup>, Daniëlle A. van der Windt<sup>1</sup>, Julius Sim<sup>1</sup>, Martyn Lewis<sup>1</sup>, Christian D. Mallen<sup>1</sup>, Elizabeth Mason<sup>1</sup>, Elaine Hay<sup>1</sup>

<sup>1</sup>Arthritis Research UK Primary Care Centre, Keele University, Keele, United Kingdom

**026 GOUT IS AN INDEPENDENT RISK FACTOR FOR ALL TYPES OF VASCULAR DISEASE: A RETROSPECTIVE COHORT STUDY IN THE UK GENERAL PRACTICE RESEARCH DATABASE**

Lorna E. Clarson<sup>1</sup>, Samantha L. Hider<sup>1</sup>, John Belcher<sup>1</sup>, Carl Heneghan<sup>2</sup>, Edward Roddy<sup>1</sup>, Christian D. Mallen<sup>1</sup>

<sup>1</sup>Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom; <sup>2</sup>Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom

**027 CASE-FINDING FOR OSTEOPOROSIS AND FRACTURE IN PRIMARY CARE**

Jane Gibson<sup>1</sup>, Susan Whiteford<sup>1</sup>, Elizabeth Williamson<sup>1</sup>, Shona Beatty<sup>2</sup>, Norma Hamilton-Dyer<sup>1</sup>

<sup>1</sup>Fife Osteoporosis Service, NHS Fife, Kirkcaldy, United Kingdom; <sup>2</sup>Department of Nursing, NHS Fife, Dunfermline, United Kingdom

**028 DEVELOPMENT OF A MODEL CONSULTATION AND TRAINING PACKAGE FOR PRACTICE NURSES TO SUPPORT SELF-MANAGEMENT OF PATIENTS CONSULTING WITH OSTEOARTHRITIS IN PRIMARY CARE**

Emma L. Healey<sup>1</sup>, Sarah Ryan<sup>2,3</sup>, Gretl A. McHugh<sup>4,1</sup>, Chris J. Main<sup>1</sup>, Mark Porcheret<sup>1</sup>, Bie Nio Ong<sup>1</sup>, Angela Pushpa-Rajah<sup>1</sup>, Krysia S. Dziedzic<sup>1</sup>

<sup>1</sup>Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom; <sup>2</sup>Staffordshire Rheumatology Centre, The Haywood Hospital, Stoke-on-Trent, United Kingdom; <sup>3</sup>School of Nursing and Midwifery, Keele University, Keele, United Kingdom; <sup>4</sup>School of Nursing, Midwifery and Social Work, The University of Manchester, Manchester, United Kingdom



**Arthritis Research UK silver medal physiotherapy**

**O29 ROCKER SOLE SHOES ARE NO MORE BENEFICIAL THAN FLAT SOLE SHOES IN THE MANAGEMENT OF CHRONIC LOW BACK PAIN**

Catharine S. MacRae<sup>1,2</sup>, Adam Shortland<sup>3,4</sup>, Jeremy Lewis<sup>5,6</sup>, Matthew Morrissey<sup>7</sup>, Duncan Critchley<sup>1</sup>

<sup>1</sup>Health and Social Care Research, King's College London, London, United Kingdom; <sup>2</sup>Therapy Services, Chelsea and Westminster NHS Foundation Trust, London, United Kingdom; <sup>3</sup>Biomedical Engineering, King's College London, London, United Kingdom; <sup>4</sup>One Small Step Gait Laboratory, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; <sup>5</sup>Musculoskeletal Services, Central London Community Healthcare, London, United Kingdom; <sup>6</sup>Physiotherapy Department, St George's Healthcare NHS Trust, London, United Kingdom; <sup>7</sup>Faculty of Health Sciences, University of Ljubljana, Slovenia

**O30 THE RISK OF A SUBSEQUENT CANCER DIAGNOSIS AFTER PMR: A PRIMARY CARE DATABASE STUDY**

Sara Muller<sup>1</sup>, Christian D. Mallen<sup>1</sup>, John Belcher<sup>1</sup>, Toby Helliwell<sup>1</sup>, Samantha L. Hider<sup>1</sup>

<sup>1</sup>Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom

**OA AND METABOLIC BONE DISEASE 14.30-16.00**

**O31 MATERNAL MILK INTAKE IS ASSOCIATED WITH INCREASED OFFSPRING BONE MINERAL CONTENT**

Zoe Cole<sup>1</sup>, Camille Parsons<sup>1</sup>, Sarah Crozier<sup>1</sup>, Sian Robinson<sup>1</sup>, Patricia Taylor<sup>2</sup>, Hazel Inskip<sup>1</sup>, Keith Godfrey<sup>1</sup>, Elaine Dennison<sup>1</sup>, Nicholas C. Harvey<sup>1</sup>, Cyrus Cooper<sup>1</sup>

<sup>1</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; <sup>2</sup>Medical Physics and Bioengineering, University Hospital Southampton, Southampton, United Kingdom

**O32 BISPHOSPHONATE USE AND IMPROVED IMPLANT SURVIVAL: A NATION-WIDE COHORT STUDY**

Daniel Prieto Alhambra<sup>1,2</sup>, Arief Lalmohamed<sup>3</sup>, Bo Abrahamsen<sup>4,5</sup>, Nigel Arden<sup>1,2</sup>, Anthonius de Boer<sup>3</sup>, Peter Vestergaard<sup>6</sup>, Frank de Vries<sup>2,3</sup>

<sup>1</sup>Oxford NIHR Musculoskeletal Biomedical Research Unit; Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; <sup>2</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; <sup>3</sup>Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, Netherlands; <sup>4</sup>Department of Medicine, Gentofte Hospital, Hillerød, Denmark; <sup>5</sup>OPEN, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark; <sup>6</sup>Aalborg Hospital, Aalborg University, Aalborg, Denmark

**O33 MORTALITY FOLLOWING ELECTIVE TOTAL HIP REPLACEMENT AND HIP RESURFACING**

Adrian Kendal<sup>1</sup>, Andrew Carr<sup>1</sup>, Daniel Prieto-Alhambra<sup>1,2</sup>, Andrew Judge<sup>1,2</sup>

<sup>1</sup>NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom; <sup>2</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom

**O34 EFFECT OF STRONTIUM RANELATE ON KNEE PAIN IN OSTEOARTHRITIS: A RESPONDER ANALYSIS**

Cyrus Cooper<sup>1</sup>, Roland Chapurlat<sup>2</sup>, Nicholas Bellamy<sup>3</sup>, Edward Czerwinski<sup>4</sup>, Jean Pierre Devogelaer<sup>5</sup>, Lynn March<sup>6</sup>, Karel Pavelka<sup>7</sup>, Jean-Yves Reginster<sup>8</sup>

<sup>1</sup>University of Southampton, MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom; <sup>2</sup>INSERM UMR 1033, Université de Lyon, Lyon, France; <sup>3</sup>CONROD, University of Queensland, Herston, QLD, Australia; <sup>4</sup>Krakowskie Medical Centre, University of Krakow, Krakow, Poland; <sup>5</sup>Cliniques Universitaires St. Luc Service de Rhumatologie, University of Brussels, Brussels, Belgium; <sup>6</sup>Institute of Bone and Joint Research, University of Sydney, Sydney, NSW, Australia; <sup>7</sup>Department of Rheumatology, University of Prague, Prague, Czech Republic; <sup>8</sup>Department of Public Health Epidemiology, University of Liege, Liege, Belgium



**O35 PREDICTORS OF POOR LONG-TERM OUTCOME IN PHYSICAL FUNCTION FOLLOWING TKA**

Amit Kiran<sup>1</sup>, Andrew Judge<sup>1,2</sup>, Muhammad K. Javaid<sup>1,2</sup>, Nigel Arden<sup>1,2</sup>, Cyrus Cooper<sup>1,2</sup>


<sup>1</sup>NIHR Musculoskeletal Biomedical Research Unit (NDORMS), University of Oxford, Oxford, United Kingdom;

<sup>2</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom

**O36 PEGLOTICASE FOR REFRACTORY GOUT: EFFICACY AND SAFETY SUMMARY OF THE GOUT1 AND GOUT2 PHASE III TRIALS**

John S. Sundry<sup>1</sup>, Herbert S. Baraf<sup>2</sup>, Michael Becker<sup>3</sup>, Edward L. Treadwell<sup>4</sup>, Robert Yood<sup>5</sup>, Faith D. Ottery<sup>6</sup>

<sup>1</sup>Duke Clinical Research Unit, Duke University Medical Centre, Durham, NC, USA; <sup>2</sup>Rheumatology and Bone Research, Centre for Rheumatology and Bone Research, Wheaton, MD, USA; <sup>3</sup>Department of Medicine, University of Chicago, Chicago, IL, USA; <sup>4</sup>Medicine-Rheumatology/Immunology, Brody School of Medicine-East Carolina University, Greenville, NC, USA; <sup>5</sup>Rheumatology, Reliant Medical Group, Worcester, MA, USA; <sup>6</sup>Global Medical Affairs, Savient Pharmaceuticals, Inc, Bridgewater, NJ, USA



Poster viewing  
Wed 24 April 2013



Awards



Poster tour

Don't forget  
to sign up for  
poster tours!

## BHPR: AUDIT AND CLINICAL EVALUATION

### 103 DENTAL HEALTH IN CHILDREN AND YOUNG ADULTS WITH INFLAMMATORY ARTHRITIS: ACCESS TO DENTAL CARE

Patricia Cornell<sup>1</sup>, Anne Trehane<sup>1</sup>, Paul Thompson<sup>1</sup>, Fouz Rahmeh<sup>1</sup>

<sup>1</sup>Rheumatology, Poole NHS Foundation Trust, Poole, United Kingdom

### 104 PATIENT PREFERENCES FOR ROUTE OF ADMINISTRATION OF BIOLOGIC THERAPIES

Mandy Greenwood<sup>1</sup>, Tanya J. Baqai<sup>1</sup>, Susanna Cambridge<sup>1</sup>, Maliha Shaikh<sup>1</sup>, Margaretta Rooney<sup>1</sup>, Simon Donnelly<sup>1</sup>, Hasan Tahir<sup>1</sup>

<sup>1</sup>Whipps Cross University Hospital, London, United Kingdom

### 105 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS: EDUCATION AND REVIEW, ARE WE DOING ENOUGH?

Sarah Ryan<sup>1</sup>, Sanjeet Kamath<sup>1</sup>, Andrew Hassell<sup>1,2</sup>

<sup>1</sup>Haywood Rheumatology Centre, Haywood Hospital, Staffordshire and Stoke on Trent Partnership NHS Trust, Stoke on Trent, United Kingdom; <sup>2</sup>School of Medicine, Keele University, Keele, United Kingdom

### 106 ARE MULTIDISCIPLINARY INPATIENT REHABILITATION PROGRAMMES EFFECTIVE FOR CHRONIC MUSCULOSKELETAL CONDITIONS? A SERVICE EVALUATION

William J. McCuish<sup>1</sup>, Lindsay Bearne<sup>2</sup>

<sup>1</sup>Rheumatology Department, Sussex Community NHS Trust, Bognor Regis, United Kingdom; <sup>2</sup>Division of Health and Social Care Research, Kings College London, London, United Kingdom

### 107 RESPONDING TO A METHOTREXATE 'NEVER EVENT': REDUCING RISKS AND RAISING AWARENESS

Bronwen Mackenzie-Green<sup>1</sup>, Elizabeth Price<sup>1</sup>, Lyn Williamson<sup>1</sup>, David Collins<sup>1</sup>

<sup>1</sup>Rheumatology, Great Western Hospital, Swindon, United Kingdom

### 108 AN OVERVIEW OF RITUXIMAB-RELATED HYPOGAMMAGLOBULINAEMIA AT LOCAL PRACTICE

Elaine Tang<sup>1</sup>, Junita Hayes<sup>1</sup>, Yoke-Mei McLoughlin<sup>1</sup>, Victoria Chamberlain<sup>1</sup>, Sophie Campbell<sup>1</sup>, Preeti Shah<sup>1</sup>, Frank McKenna<sup>1</sup>

<sup>1</sup>Rheumatology, Trafford General Hospital, Central Manchester Hospital NHS Trust, Manchester, United Kingdom

### 109 TIGHT CONTROL WITH REGULAR REVIEW FOR RHEUMATOID ARTHRITIS IN A DGH REDUCES THE USE OF BIOLOGIC THERAPY ACCORDING TO NICE GUIDELINES EVEN IF MODERATE DISEASE ACTIVITY WAS TREATED

Patricia Cornell<sup>1</sup>, Sarah Westlake<sup>1</sup>, Paul Thompson<sup>1</sup>, Selwyn Richards<sup>1</sup>

<sup>1</sup>Rheumatology, Poole NHS Foundation Trust, Poole, United Kingdom

### 110 IMPLEMENTING COMMISSIONING FOR QUALITY IN RHEUMATOID ARTHRITIS OUTCOME METRICS IN A NEW ONSET RA COHORT IN PRIMARY CARE

Dawn Homer<sup>1</sup>, Erica Gould<sup>1</sup>, Ben Empson<sup>1</sup>, Paul Kemp<sup>1</sup>

<sup>1</sup>Vitality Partnership - Community Rheumatology Service, Birmingham, United Kingdom

### 111 DOES OCCUPATIONAL THERAPY/PHYSIOTHERAPY STILL HAVE A ROLE IN THE MANAGEMENT OF INFLAMMATORY ARTHRITIS WITH THE EMERGENCE OF BIOLOGICS AND TREAT-TO-TARGET PROTOCOLS?

Amanda G. Richards<sup>1</sup>, Jill Walker<sup>1</sup>, Sophie Taylor<sup>1</sup>

<sup>1</sup>Therapies, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom

### 112 RITUXUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS: AN ALL-WALES AUDIT

Syed F. Bari<sup>1</sup>, Malack Alachkar<sup>2</sup>, Rizwan Rajak<sup>3</sup>,  
Tom Lawson<sup>1</sup>, Margaret O'Sullivan<sup>2</sup>

<sup>1</sup>Rheumatology, Princess of Wales Hospital, Bridgend, United Kingdom; <sup>2</sup>Rheumatology, Wrexham Maelor Hospital, Wrexham, United Kingdom; <sup>3</sup>Rheumatology, University Hospital of Wales, Cardiff, United Kingdom

### 113 RITUXIMAB USED ON AN ON-DEMAND BASIS FOR RHEUMATOID ARTHRITIS PATIENTS; A COST-SAVINGS ANALYSIS

Shivram Samant<sup>1</sup>, Sayqa Butt<sup>2</sup>, Kate Gadsby<sup>2</sup>

<sup>1</sup>Graduate Entry Medical School, University of Nottingham, Nottingham, United Kingdom; <sup>2</sup>Rheumatology Department, Royal Derby Hospital, Derby, United Kingdom

## BHPR RESEARCH: QUALITATIVE

### 114 "IT'S LIKE A JUGGLING ACT": RA PATIENTS EXPERIENCE A LIFE OF 'FLUCTUATING BALANCES'

Caroline A. Flurey<sup>1</sup>, Marianne Morris<sup>1</sup>, Rodney Hughes<sup>2</sup>,  
Jon Pollock<sup>1</sup>, Pam Richards<sup>3</sup>, Sarah Hewlett<sup>1</sup>

<sup>1</sup>Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom; <sup>2</sup>Rheumatology, Ashford and St Peter's Hospital Foundation Trust, Chertsey, United Kingdom; <sup>3</sup>Rheumatology, University of Bristol, Bristol, United Kingdom

### 115 LIVING WITH RHEUMATOID ARTHRITIS AND FIBROMYALGIA: THE PATIENT EXPERIENCE

Kirsty R. Edwards<sup>1</sup>, Ian Rowe<sup>1</sup>

<sup>1</sup>Rheumatology OPD, WRH NHS Trust, Worcester, United Kingdom

### 116 MANAGING SCIATICA IN THE PHYSIOTHERAPY CONSULTATION: A QUALITATIVE OBSERVATION AND INTERVIEW STUDY

Tom Sanders<sup>1</sup>, Kate Dunn<sup>1</sup>, Kika Konstantinou<sup>1</sup>, Elaine Hay<sup>1</sup>

<sup>1</sup>Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom

### 117 THE THOUGHTS AND FEELINGS HELD BY CLINICIANS ABOUT THE DELIVERY OF A PLACEBO INTERVENTION IN AN OSTEOARTHRITIS REHABILITATION TRIAL

Lucy E. Jones<sup>1</sup>, Jo Adams<sup>1</sup>, Peter White<sup>1</sup>,  
Maggie Donovan-Hall<sup>1</sup>, Kelly Hislop<sup>1</sup>, Sofia Barbosa Bouças<sup>1</sup>

<sup>1</sup>Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom

### 118 FACTORS AFFECTING ADHERENCE TO THE SARAH TRIAL HAND EXERCISE PROGRAMME FOR RHEUMATOID ARTHRITIS: AN INTERVIEW STUDY

Vivien P. Nichols<sup>1</sup>, Esther M. Williamson<sup>1</sup>, Francine Toye<sup>2</sup>,  
Sarah E. Lamb<sup>1</sup>, Sarah Trial Team<sup>1</sup>

<sup>1</sup>Warwick Clinical Trials Unit, The University of Warwick, Coventry, United Kingdom; <sup>2</sup>Physiotherapy Research Unit, Nuffield Orthopaedic Centre, Oxford, United Kingdom

### 119 EXPLORING THE NATURE AND EVOLVING PROCESSES OF ONLINE SUPPORT IN A NEWLY DEVELOPED FORUM FOR PEOPLE WITH COMPLEX REGIONAL PAIN SYNDROME



Karen Rodham<sup>1,2</sup>, Jeffrey Gavin<sup>1</sup>, Leon Watts<sup>3</sup>, Neil Coulson<sup>4</sup>

<sup>1</sup>Psychology, University of Bath, Bath, United Kingdom; <sup>2</sup>BCPS, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; <sup>3</sup>Computer Science, University of Bath, Bath, United Kingdom; <sup>4</sup>Faculty of Medicine and Health Sciences, University of Nottingham, Nottingham, United Kingdom

### 120 THE ILLNESS NARRATIVES OF INDIVIDUALS NEWLY DIAGNOSED WITH FIBROMYALGIA

Claire Diver<sup>1</sup>, Mark Avis<sup>1</sup>, Anindya Gupta<sup>2</sup>

<sup>1</sup>School of Nursing, Midwifery and Physiotherapy, University of Nottingham, Nottingham, United Kingdom; <sup>2</sup>Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

**121 FIBROMYALGIA PATIENTS EXPERIENCES OF THE MANAGEMENT OF THEIR CONDITION**

Sarah-Jane Ryan<sup>1</sup>, Sarah Stangroom<sup>2</sup>

<sup>1</sup>School of Health Professions, University of Brighton, Eastbourne, United Kingdom; <sup>2</sup>Physiotherapy Department, Southern Health NHS Foundation Trust, Eastleigh, United Kingdom

**122 IDENTITY IN MEN WITH CHRONIC LOW BACK PAIN**

Julian M. Pearce<sup>1</sup>, Jenny Byrne<sup>2</sup>

<sup>1</sup>Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom; <sup>2</sup>Education School, University of Southampton, Southampton, United Kingdom

**123 "I THINK HAVING A PROGRAMME LIKE THAT FOR PEOPLE WHO HAVE GOT RHEUMATOID ARTHRITIS IS WELL WORTH DOING": EXPERIENCES OF AN UPPER LIMB EDUCATION, SELF-MANAGEMENT, AND EXERCISE PROGRAMME AMONG PEOPLE WITH EARLY RHEUMATOID ARTHRITIS**

Victoria L. Manning<sup>1</sup>, Michael Hurley<sup>2</sup>, David L. Scott<sup>1</sup>, Ernest Choy<sup>3</sup>, Lindsay Bearne<sup>1</sup>

<sup>1</sup>School of Medicine, King's College London, London, United Kingdom; <sup>2</sup>School of Rehabilitation Sciences, St. George's University of London and Kingston University, London, United Kingdom; <sup>3</sup>Cardiff Institute of Infection and Immunity, Cardiff University, Cardiff, United Kingdom

**124 PRAGMATIST, EMOTION-FOCUSED FIGHTER, PROBLEM-FOCUSED FIGHTER OR MINIMISER? POSSIBLE TRAJECTORIES OF NEWLY DIAGNOSED PATIENTS**



Julie Taylor<sup>1</sup>, Marianne Morris<sup>1</sup>, Emma Dures<sup>2</sup>, Sarah Hewlett<sup>1</sup>

<sup>1</sup>Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom; <sup>2</sup>Academic Rheumatology, University Hospital Bristol NHS Trust, Bristol, United Kingdom

**125 ADHERENCE TO EXERCISE AND PHYSICAL ACTIVITY IN OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS**

Alison Wilson<sup>1</sup>, Jo Adams<sup>1</sup>

<sup>1</sup>Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom

**BHPR RESEARCH: QUANTITATIVE**

**126 AN EXAMINATION OF SELF-REPORT PHYSICAL ACTIVITY AND ITS RELATIONSHIP WITH PSYCHOLOGICAL FACTORS IN INFLAMMATORY ARTHRITIS**

Louise Larkin<sup>1</sup>, Norelee Kennedy<sup>1</sup>, Stephen Gallagher<sup>2</sup>, Alexander D. Fraser<sup>3,4</sup>

<sup>1</sup>Department of Clinical Therapies, University of Limerick, Limerick, Ireland; <sup>2</sup>Department of Psychology, University of Limerick, Limerick, Ireland; <sup>3</sup>Medical School, University of Limerick, Limerick, Ireland; <sup>4</sup>Department of Rheumatology, Limerick University Hospitals, Limerick, Ireland

**127 EFFECT OF BODY MASS INDEX ON CLINICAL RESPONSE TO ANTI-TNF THERAPIES IN RHEUMATOID ARTHRITIS: A RETROSPECTIVE STUDY**



Parul Shrestha<sup>1</sup>, Michael Batley<sup>2</sup>, Gouri Koduri<sup>2</sup>, David L. Scott<sup>3</sup>

<sup>1</sup>St.Georges Hospital, London, United Kingdom; <sup>2</sup>Rheumatology, Maidstone Hospital, Maidstone, United Kingdom; <sup>3</sup>Rheumatology, Kings College Hospital, London, United Kingdom

**128 RA FLARES: INFLAMMATION OR AVALANCHE?**



Caroline A. Flurey<sup>1</sup>, Marianne Morris<sup>1</sup>, Rodney Hughes<sup>2</sup>, Jon Pollock<sup>1</sup>, Pam Richards<sup>3</sup>, Sarah Hewlett<sup>1</sup>

<sup>1</sup>Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom; <sup>2</sup>Rheumatology, Ashford and St Peter's NHS Foundation Trust, Chertsey, United Kingdom; <sup>3</sup>Rheumatology, University of Bristol, Bristol, United Kingdom

**129 ADHERENCE TO DISEASE MODIFYING ANTI-RHEUMATIC DRUGS AMONGST SOUTH ASIAN AND WHITE BRITISH PATIENTS WITH RHEUMATOID ARTHRITIS: A CROSS-SECTIONAL STUDY**



Kanta Kumar<sup>1</sup>, Karim Raza<sup>2</sup>, Peter Nightingale<sup>3</sup>, Rob Horne<sup>4</sup>, Sarah Chapman<sup>4</sup>, Sheila Greenfield<sup>1</sup>, Paramjit Gill<sup>1</sup>

<sup>1</sup>School of Health and Population Sciences, University of Birmingham, Birmingham, United Kingdom; <sup>2</sup>School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; <sup>3</sup>Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom; <sup>4</sup>School of Pharmacy, University College London, London, United Kingdom

**130 THE STABILITY OF ILLNESS BELIEFS IN RHEUMATOID ARTHRITIS: A PILOT FOLLOW-UP STUDY**

Anna M. Ferguson<sup>1,2</sup>, Fowzia Ibrahim<sup>2</sup>, David L. Scott<sup>2</sup>, Heidi Lempp<sup>2</sup>

<sup>1</sup>Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; <sup>2</sup>Academic Department of Rheumatology, King's College London, London, United Kingdom

**131 COMPARISON OF ENERGY EXPENDITURE LEVELS BETWEEN RA SUBJECTS AND CONTROLS**

Marie Tierney<sup>1</sup>, Alexander Fraser<sup>2</sup>, Norelee Kennedy<sup>1</sup>

<sup>1</sup>Clinical Therapies, University of Limerick, Limerick, Ireland; <sup>2</sup>Rheumatology, Mid-Western Regional Hospitals, Limerick, Ireland

**132 DEFINING OPTIMAL NHS OCCUPATIONAL THERAPY TREATMENT, INDIVIDUALISED SPLINT, AND PLACEBO SPLINT FOR PATIENTS WITH THUMB BASE OA: A DELPHI STUDY**

Sofia Barbosa Boucas<sup>1</sup>, Kelly Hislop<sup>1</sup>, Krysia Dziedzic<sup>2</sup>, Nigel Arden<sup>3</sup>, Jane Burridge<sup>1</sup>, Alison Hammond<sup>4</sup>, Maria Stokes<sup>1</sup>, Martyn Lewis<sup>2</sup>, Rachael Gooberman-Hill<sup>5</sup>, Karen Coales<sup>1</sup>, Jo Adams<sup>1</sup>

<sup>1</sup>Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom; <sup>2</sup>Arthritis Research UK Primary Care Centre, Clinical Trials Unit, Institute of Primary Care and Health Sciences, Keele University, Keele, United Kingdom; <sup>3</sup>The Botnar Research Centre Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom; <sup>4</sup>Centre for Rehabilitation and Human Performance Research, University of Salford, Salford, United Kingdom; <sup>5</sup>Orthopaedic Surgery Research Group, Musculoskeletal Research Unit, School of Clinical Sciences, University of Bristol, Bristol, United Kingdom

**133 USE OF WII FIT® IN BALANCE TRAINING IN OSTEOPOROSIS**



Helen Nutland<sup>1</sup>, Allison Dean<sup>1</sup>, Ramasharan Laxminarayan<sup>1</sup>

<sup>1</sup>Rheumatology, Queen's Hospital, Burton upon Trent, United Kingdom

**134 AN INVESTIGATION INTO THE PREVALANCE OF DISABLING FOOT PAIN IN PATIENTS AWAITING TOTAL KNEE ARTHROPLASTY**



Lucy Gates<sup>1</sup>, Catherine Bowen<sup>1</sup>, Nigel Arden<sup>2,3</sup>

<sup>1</sup>Faculty of Health Sciences, University of Southampton, Southampton, United Kingdom; <sup>2</sup>MRC Epidemiology Resource Centre, University of Southampton, Southampton, United Kingdom; <sup>3</sup>Biomedical Research Unit, University of Oxford, Oxford, United Kingdom

**135 THE MEASUREMENT PROPERTIES OF THE DUTCH KEELE ASSESSMENT OF PARTICIPATION QUESTIONNAIRE IN OLDER ADULTS WITH JOINT PAIN AND COMORBIDITY**

Lotte Hermesen<sup>1</sup>, Caroline B. Terwee<sup>2</sup>, Stephanie S. Leone<sup>1</sup>, Babette vd Zwaard<sup>1</sup>, Martin Smalbrugge<sup>1</sup>, Joost Dekker<sup>3</sup>, Henriëtte vd Horst<sup>1</sup>, Ross Wilkie<sup>4</sup>

<sup>1</sup>General Practice and Elderly Care Medicine and the EMGO Institute for Health and Care Research, VUmc, Amsterdam, Netherlands; <sup>2</sup>Epidemiology and Biostatistics and the EMGO Institute for Health and Care Research, VUmc, Amsterdam, Netherlands; <sup>3</sup>Rehabilitation Medicine and the EMGO Institute for Health and Care Research, VUmc, Amsterdam, Netherlands; <sup>4</sup>Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom



**136 IMPROVING ADHERENCE IN RHEUMATOID ARTHRITIS: A PILOT STUDY**

Anna M. Ferguson<sup>1</sup>, Veronica Nicky Thomas<sup>2</sup>, Heidi Lempp<sup>3</sup>, Andrew Cope<sup>1</sup>, David L. Scott<sup>4</sup>, Carol Simpson<sup>3</sup>, John Weinman<sup>5</sup>, Sangita Agarwal<sup>1</sup>, Bruce Kirkham<sup>1</sup>, Anita Patel<sup>6</sup>, Fowzia Ibrahim<sup>3</sup>

<sup>1</sup>Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom; <sup>2</sup>Haematology, Guy's Hospital, London, United Kingdom; <sup>3</sup>Academic Department of Rheumatology, King's College London, London, United Kingdom; <sup>4</sup>Rheumatology, King's College Hospital, London, United Kingdom; <sup>5</sup>Health Psychology Section, Psychology Department (Guy's Hospital), Institute of Psychiatry, London, United Kingdom; <sup>6</sup>Centre for the Economics of Mental Health, Institute of Psychiatry at King's College London, London, United Kingdom



Arthritis Research UK silver medal research prize winner

**137 TIBIALIS POSTERIOR TENOSYNOVITIS IN RA: RESPONSE TO ORTHOTIC AND CORTICOSTEROID INTERVENTION**

Ruth Barn<sup>1,2</sup>, Mhairi Brandon<sup>3</sup>, Daniel Rafferty<sup>2</sup>, Roger Sturrock<sup>3</sup>, Deborah Turner<sup>2</sup>, James Woodburn<sup>2</sup>

<sup>1</sup>Department of Psychology and Allied Health Sciences, Glasgow Caledonian University, Glasgow, United Kingdom; <sup>2</sup>Institute for Applied Health Research, Glasgow Caledonian University, Glasgow, United Kingdom; <sup>3</sup>Centre for Rheumatic Diseases, Glasgow Royal Infirmary, Glasgow, United Kingdom

**138 OBJECTIVELY MEASURED SEDENTARY BEHAVIOUR AND PHYSICAL ACTIVITY IN RHEUMATOID ARTHRITIS**

Daniel Rafferty<sup>1</sup>, Lorna Paul<sup>2</sup>, Rebecca Marshall<sup>2</sup>, Jason Gill<sup>3</sup>, Iain McInnes<sup>4</sup>, Duncan Roderick Porter<sup>4</sup>, James Woodburn<sup>1</sup>

<sup>1</sup>School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, United Kingdom; <sup>2</sup>School of Medicine, University of Glasgow, Glasgow, United Kingdom; <sup>3</sup>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; <sup>4</sup>Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom



**139 CRITICAL APPRAISAL OF CLINICAL PRACTICE GUIDELINES FOR FOOT AND ANKLE MANAGEMENT IN RHEUMATOID ARTHRITIS**

Kym Hennessy<sup>1</sup>, James Woodburn<sup>1</sup>, Martijn Steultjens<sup>1</sup>

<sup>1</sup>Institute for Applied Health Research, School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, United Kingdom

**140 LONGITUDINAL FOLLOW UP OF PLANTAR PLATE PATHOLOGY IN THE PAINFUL FOREFOOT OF PATIENTS WITH RHEUMATOID ARTHRITIS**

Heidi J. Siddle<sup>1</sup>, Richard J. Hodgson<sup>2</sup>, Elizabeth M. Hensor<sup>1</sup>, Andrew J. Grainger<sup>2,3</sup>, Anthony Redmond<sup>1,2</sup>, Richard J. Wakefield<sup>1,2</sup>, Philip S. Helliwell<sup>1</sup>

<sup>1</sup>Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom; <sup>2</sup>NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; <sup>3</sup>Department of Radiology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

**141 THE LIFESTYLE MANAGEMENT FOR ARTHRITIS PROGRAMME IN PRACTICE: RESULTS OF AN OBSERVATIONAL STUDY**

Alison Hammond<sup>1</sup>, Joanne Rayner<sup>2</sup>

<sup>1</sup>Centre for Health Sciences, University of Salford, Salford, <sup>2</sup>Rheumatology, Royal Derby Hospital, Derby, United Kingdom



**142 THE EFFECTS OF EXERCISE TRAINING ON CARTILAGE BREAKDOWN, SYNOVIAL AND SYSTEMIC INFLAMMATION IN RA**

Rebecca-Jane Law<sup>1,2</sup>, Anne Breslin<sup>3</sup>, Alexandra Kraus<sup>3</sup>, Peter Maddison<sup>2</sup>, Jeanette M. Thom<sup>2</sup>

<sup>1</sup>School of Sport, Tourism and The Outdoors, University of Central Lancashire, Preston, United Kingdom; <sup>2</sup>School of Sport, Health and Exercise Sciences, Bangor University, Bangor, United Kingdom; <sup>3</sup>Rheumatology Department, Betsi Cadwaladr University Health Board, Llandudno, United Kingdom



**143 FOOT INVOLVEMENT IN EARLY RHEUMATOID ARTHRITIS STUDY: A PROSPECTIVE STUDY INVESTIGATING CHANGE IN ULTRASOUND FEATURES, IMPAIRMENT AND DISABILITY**

Lisa W. Newcombe<sup>1</sup>, James Woodburn<sup>1</sup>, Duncan Porter<sup>2</sup>, Sarah Saunders<sup>3</sup>, David McCarey<sup>3</sup>, Monica Gupta<sup>4</sup>, Deborah Turner<sup>1</sup>

<sup>1</sup>Institute for Applied Health Research, Glasgow Caledonian University, Glasgow, United Kingdom; <sup>2</sup>Department of Rheumatology, University of Glasgow, Glasgow, United Kingdom; <sup>3</sup>Department of Rheumatology Out-patients, Glasgow Royal Infirmary, Glasgow, United Kingdom; <sup>4</sup>Department of Rheumatology Out-patients, Gartnavel General Hospital, Glasgow, United Kingdom

**BIOLOGY OF BONE, CARTILAGE AND CONNECTIVE TISSUE DISEASE**

**144 CRITICAL ROLE FOR PAR-2 IN HUMAN OSTEOCLAST DIFFERENTIATION IN VITRO**

Laura McGavin<sup>1,2</sup>, Robin Freeburn<sup>1</sup>, Anne Crilly<sup>1,2</sup>, John C. Lockhart<sup>1,2</sup>, William R. Ferrell<sup>1,2</sup>, Carl Goodyear<sup>1,2</sup>

<sup>1</sup>School of Science, University of the West of Scotland, Paisley, United Kingdom; <sup>2</sup>Institute of Immunity, Infection and Inflammation, University of Glasgow, Glasgow, United Kingdom

**EDUCATION**

**145 PREFERENCES WHEN APPLYING TO RHEUMATOLOGY SPECIALIST TRAINING PROGRAMMES**

Joanna Ledingham<sup>1</sup>, Tom Waterman<sup>2</sup>, Liz Berkin<sup>2</sup>

<sup>1</sup>Rheumatology Department, Queen Alexandra Hospital, Portsmouth, United Kingdom; <sup>2</sup>Specialty Recruitment Office, Royal College of Physicians, London, United Kingdom

**146 THE USE OF ONLINE HEALTH INFORMATION BY ARTHRITIS PATIENTS: A SYSTEMATIC REVIEW**

Michael Nicolaou<sup>1</sup>, Pippa Watson<sup>2</sup>, Mark Lillicrap<sup>2</sup>, Fraser Birrell<sup>1,3</sup>

<sup>1</sup>Rheumatology, Northumbria Healthcare Foundation Trust, Ashington, United Kingdom; <sup>2</sup>Rheumatology, Hinchingsbrooke Hospital, Hinchingsbrooke Park, Huntingdon, United Kingdom; <sup>3</sup>Musculoskeletal Research Group, Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom

**147 THE INFORMATIONAL NEEDS OF PATIENTS WITH ANCA-VASCULITIS: A MULTINATIONAL STUDY**

Janice Mooney<sup>1</sup>, Peter A. Merkel<sup>2</sup>, Fiona Poland<sup>1</sup>, Nicola Spalding<sup>1</sup>, Peter Grayson<sup>3</sup>, Renee Leduc<sup>4</sup>, Denise Shereff<sup>4</sup>, Rachel Richesson<sup>4</sup>, Richard A. Watts<sup>1</sup>

<sup>1</sup>Norwich Medical School, University of East Anglia, Norwich, United Kingdom; <sup>2</sup>Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA; <sup>3</sup>Vasculitis Centre, Boston University, Boston, MA, USA; <sup>4</sup>Vasculitis Clinical Research Consortium, National Institutes of Health Rare Diseases Clinical Research Network, Tampa, FL, USA

**148 SPECIALTIES CHOSEN FOR FOUNDATION YEARS TRAINING BY MEDICAL STUDENTS ARE RELATED TO CAREER CHOICE: IS RHEUMATOLOGY WOMEN'S PREFERENCE AMONGST MEDICAL STUDENTS?**

Euthalia Roussou<sup>1,2</sup>, Muryum Thapper<sup>2</sup>

<sup>1</sup>Rheumatology, BHRUT, Goodmayes, United Kingdom; <sup>2</sup>Medicine and Dentistry, QMUL, London, United Kingdom

**149 VIRTUAL PATIENTS FOR RHEUMATOLOGY EDUCATION: PRELIMINARY RESULTS FROM A MULTI-CENTRE STUDY**

James Bateman<sup>1,2</sup>, Maggie Allen<sup>2</sup>, Jane Kidd<sup>1</sup>, Nick Parsons<sup>3</sup>, David Davies<sup>1</sup>

<sup>1</sup>Department for Medical Education Research, University of Warwick, Coventry, United Kingdom; <sup>2</sup>Department of Rheumatology, University Hospital Coventry and Warwickshire NHS Trust, Coventry, United Kingdom; <sup>3</sup>Department of Statistics, Warwick Medical School, Coventry, United Kingdom



Medical student bursary winner



**150 CAN MEDICAL STUDENTS SUCCESSFULLY ENGAGE WITH THEIR PEERS TO ENCOURAGE INTEREST IN MUSCULOSKELETAL MEDICINE AND SURGERY? THE FIRST NATIONAL UNDERGRADUATE MUSCULOSKELETAL CONFERENCE**

Kelsey A. Watt<sup>1</sup>, Mark D. Scally<sup>1</sup>

<sup>1</sup>Wolfson Medical School, University of Glasgow, Glasgow, United Kingdom

**151 IMPACT OF RA ON EMOTIONS, RELATIONSHIPS AND INTIMACY**

Ailsa Bosworth<sup>1</sup>, Kate Wilkinson<sup>1</sup>, Sarah Collins<sup>1</sup>, Clare B. Jacklin<sup>1</sup>

<sup>1</sup>External Affairs, National Rheumatoid Arthritis Society, Maidenhead, United Kingdom

**152 THE VALUE OF SOCIAL MEDIA TO THOSE LIVING WITH RHEUMATOID ARTHRITIS**

Sarah K. Ball<sup>1</sup>, Ruth Grosart<sup>2</sup>

<sup>1</sup>Helpline, National Rheumatoid Arthritis Society, Maidenhead, United Kingdom; <sup>2</sup>Fundraising, National Rheumatoid Arthritis Society, Maidenhead, United Kingdom

**153 SURVEY OF JOINT INJECTION PRACTICE WITHIN WESSEX DEANERY**

Jonathan Marks<sup>1</sup>, Anna E. Litwic<sup>2</sup>, Melonie K. Sriranganathan<sup>3</sup>, Sandeep Mukherjee<sup>2</sup>, Muhammad A. Khurshid<sup>2</sup>

<sup>1</sup>Department of Rheumatology, Hampshire Hospitals Foundation Trust, Basingstoke, United Kingdom; <sup>2</sup>Department of Rheumatology, University Hospital Southampton, Southampton, United Kingdom; <sup>3</sup>Department of Rheumatology, Queen Alexandra Hospital, Portsmouth, United Kingdom

**154 DEVELOPMENT OF A NURSE-LED ULTRASOUND-GUIDED JOINT INJECTION SERVICE AT CANNOCK**

Susan M. Matthews<sup>1</sup>, Alison Hall<sup>1,2</sup>, Tom Sheeran<sup>1</sup>, Sangeetha Baskar<sup>1</sup>

<sup>1</sup>Rheumatology, Cannock Chase Hospital, Cannock, United Kingdom; <sup>2</sup>Rheumatology, Keele University, Keele, United Kingdom

**155 DID THE 2012 OLYMPIC GAMES INSPIRE A GENERATION OF RHEUMATOLOGY PATIENTS TO EXERCISE?**

Michael Muether<sup>1</sup>, Bronwen Mackenzie-Green<sup>1</sup>, Amy Hetherington<sup>1</sup>, Gayani Wickrematilake<sup>1</sup>, Lyn Williamson<sup>1</sup>

<sup>1</sup>Rheumatology, Great Western Hospital Swindon, Swindon, United Kingdom

**156 FACTORS INFLUENCING A CAREER CHOICE IN RHEUMATOLOGY**

Louise E. Daniels<sup>1,2</sup>

<sup>1</sup>Rheumatology, South London NHS Trust, Sidcup, United Kingdom; <sup>2</sup>Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

**157 OPTIMISING UNDERGRADUATE STUDENT-PATIENT INTERACTION IN A DISTRICT GENERAL HOSPITAL**

Catherine E. Gwynne<sup>1</sup>, Afsha Khan<sup>1</sup>, Tom Lawson<sup>1</sup>

<sup>1</sup>Rheumatology, Princess of Wales Hospital, Bridgend, Bridgend, United Kingdom

**OSTEOPOROSIS AND METABOLIC BONE DISEASE**

**158 HIP FRACTURE INCIDENCE OVER 7 YEARS IN A POPULATION SERVED BY A FRACTURE LIAISON SERVICE: COMPARISON WITH AN FLS-'LITE' HEALTHCARE AREA**

Gavin Clunie<sup>1</sup>, Sonya Stephenson<sup>1</sup>, Karl Gaffney<sup>2</sup>, Johnathan Belsey<sup>3</sup>

<sup>1</sup>Rheumatology Department, The Ipswich Hospital NHS Trust, Ipswich, United Kingdom; <sup>2</sup>Rheumatology Department, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom; <sup>3</sup>Medical Informatics, JB Medical, Little Cornard, United Kingdom

**159 CHILDHOOD BONE SIZE, MINERALISATION AND DENSITY ARE ASSOCIATED WITH METHYLATION STATUS OF THE CDKN2A PROMOTER AT BIRTH**

Nicholas C. Harvey<sup>1</sup>, Rebecca Clarke-Harris<sup>2</sup>, Rob Murray<sup>2</sup>, Paula Costello<sup>2</sup>, Emma Garrett<sup>2</sup>, Joanna Holbrook<sup>3</sup>, Ai-Ling Teh<sup>3</sup>, Johnny Wong<sup>3</sup>, Shaillay Dogra<sup>3</sup>, Sheila Barton<sup>1</sup>, Lucy Davies<sup>1</sup>, Hazel Inskip<sup>1</sup>, Mark Hanson<sup>2</sup>, Peter Gluckman<sup>3,4</sup>, Cyrus Cooper<sup>1</sup>, Keith Godfrey<sup>1,5</sup>, Karen Lillycrop<sup>2</sup>

<sup>1</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; <sup>2</sup>Institute of Developmental Sciences, University of Southampton, Southampton, United Kingdom; <sup>3</sup>Singapore Institute for Clinical Sciences, Agency for Science, Technology and Research, Singapore, Singapore; <sup>4</sup>Liggins Institute, University of Auckland, Auckland, New Zealand; <sup>5</sup>NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospitals Southampton NHS Foundation Trust, Southampton, United Kingdom

**160 A BRISTOL-BASED POSTAL SURVEY INVESTIGATING THE GUIDANCE USED AND ADVICE GIVEN TO THEIR PATIENTS BY GENERAL DENTAL PRACTITIONERS REGARDING BISPHOSPHONATE-INDUCED OSTEONECROSIS OF THE JAW**

Tom Anderton<sup>1</sup>, Shane Clarke<sup>2</sup>

<sup>1</sup>University of Bristol, Bristol, United Kingdom; <sup>2</sup>Department of Rheumatology, University Hospitals Bristol, Bristol, United Kingdom

**161 BISPHOSPHONATE-INDUCED ATYPICAL FEMORAL FRACTURES: ARE WE AWARE?**

Subba Rao Chaganti<sup>1</sup>, Nick Viner<sup>2</sup>, Richard Seymour<sup>1</sup>

<sup>1</sup>Radiology, Torbay Hospital, Torquay, United Kingdom; <sup>2</sup>Rheumatology, Torbay Hospital, Torquay, United Kingdom

**162 RELATIONSHIPS BETWEEN BIRTH WEIGHT AND BONE MICROARCHITECTURE IN LATE ADULTHOOD: FINDINGS FROM THE HERTFORDSHIRE COHORT STUDY**

Mark H. Edwards<sup>1</sup>, Camille Parsons<sup>1</sup>, Kate Ward<sup>2</sup>, Jennifer Thompson<sup>2</sup>, Ann Prentice<sup>2</sup>, Elaine Dennison<sup>1</sup>, Cyrus Cooper<sup>1,3</sup>

<sup>1</sup>MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, United Kingdom; <sup>2</sup>MRC Human Nutrition Research, Cambridge, United Kingdom; <sup>3</sup>Institute of Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom

**163 PREDICTING ADHERENCE TO BISPHOSPHONATES IN A POPULATION-BASED COHORT OF OLDER WOMEN**

Emma Clark<sup>1</sup>, Miranda Cumming<sup>1</sup>, Leigh Morrison<sup>1</sup>, Virginia C. Gould<sup>1</sup>, Jon Tobias<sup>1</sup>

<sup>1</sup>Academic Rheumatology, Avon Orthopaedic Centre, Bristol, United Kingdom

**164 PLACENTAL MORPHOMETRY PREDICTS BONE SIZE AND DENSITY IN 9-YEAR-OLD BRITISH CHILDREN**

Christopher R. Holroyd<sup>1</sup>, Nicola Winder<sup>1</sup>, Clive Osmond<sup>1</sup>, Caroline Fall<sup>1</sup>, David Barker<sup>1</sup>, Susan Ring<sup>2</sup>, Deborah Lawlor<sup>2</sup>, Jon Tobias<sup>2</sup>, George Davey Smith<sup>2</sup>, Cyrus Cooper<sup>1</sup>, Nicholas C. Harvey<sup>1</sup>

<sup>1</sup>MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom; <sup>2</sup>University of Bristol, Bristol, United Kingdom

**165 DOES DENOSUMAB INCREASE INFECTION RATES IN RHEUMATOID ARTHRITIS PATIENTS ON BIOLOGICS?**

Tracey E. Toms<sup>1</sup>, Shahzeb Afreedi<sup>1</sup>, Karen Salt<sup>1</sup>, Samantha Roskell<sup>1</sup>, Kathleen Passey<sup>1</sup>, Thomas Price<sup>1</sup>, Srinivasan Venkatachalam<sup>1</sup>, Thomas Sheeran<sup>1</sup>

<sup>1</sup>Rheumatology, Cannock Chase Hospital, Cannock, United Kingdom

**ADOLESCENT AND YOUNG ADULT RHEUMATOLOGY**

**166 BASELINE CO-MORBIDITIES IN PATIENTS WITH JIA STARTING ETANERCEPT OR METHOTREXATE: RESULTS FROM THE BSPAR ETANERCEPT REGISTER**

Rebecca Davies<sup>1</sup>, Taunton R. Southwood<sup>2</sup>, Lianne Kearsley-Fleet<sup>1</sup>, Kimme L. Hrych<sup>1</sup>

<sup>1</sup>Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, University of Manchester, Manchester, United Kingdom; <sup>2</sup>Institute of Child Health, The University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom

**167 SAFETY AND EFFICACY OF ADALIMUMAB IN CHILDREN WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS AGED 2 TO <4 YEARS OR ≥4 YEARS WEIGHING <15 KG**

Daniel Kingsbury<sup>1</sup>, Pierre Quartier<sup>2</sup>, Gina Patel<sup>3</sup>, Vipin Arora<sup>4</sup>, Hartmut Kupper<sup>5</sup>, Neelufar Mozaffarian<sup>6</sup>

<sup>1</sup>Pediatric Rheumatology Clinic, Legacy Emanuel Children's Hospital, Portland, OR, USA; <sup>2</sup>Unite d'Immuno-Hematologie et Rhumatologie Pediatriques, Hopital Necker-Enfants Malades, Paris, France; <sup>3</sup>Clinical Pharmacokinetics/ Pharmacodynamics, AbbVie, North Chicago, IL, USA; <sup>4</sup>Data and Statistical Sciences, AbbVie, North Chicago, IL, USA; <sup>5</sup>Immunology Development, AbbVie GmbH and Co. KG, Ludwigshafen, Germany; <sup>6</sup>Immunology Development, AbbVie, North Chicago, IL, USA

**168 USE OF NON-ETANERCEPT BIOLOGICS IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE BIOLOGICS FOR CHILDREN WITH RHEUMATIC DISEASES STUDY**

Lianne Kearsley-Fleet<sup>1</sup>, Eileen Baildam<sup>2</sup>, Michael W. Beresford<sup>3</sup>, Rebecca Davies<sup>1</sup>, Helen E. Foster<sup>4</sup>, Katy Mowbray<sup>1</sup>, Taunton R. Southwood<sup>5</sup>, Wendy Thomson<sup>1</sup>, Kimme L. Hyrich<sup>1</sup>

<sup>1</sup>Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; <sup>2</sup>Alder Hey Children's Foundation, NHS Trust, Liverpool, United Kingdom; <sup>3</sup>Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom; <sup>4</sup>Musculoskeletal Research Group, Institute Cellular Medicine, University of Newcastle, Newcastle, United Kingdom; <sup>5</sup>Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom

**169 FAMILY HISTORY OF AUTOIMMUNITY IN CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: PREVALENCE AND INFLUENCE ON DISEASE PRESENTATION: RESULTS FROM THE UK CHILDHOOD ARTHRITIS PROSPECTIVE STUDY**

Emma Saunders<sup>1</sup>, Eileen Baildam<sup>2</sup>, Alice Chieng<sup>3</sup>, Joyce Davidson<sup>4</sup>, Helen Foster<sup>5</sup>, Janet Gardner-Medwin<sup>4</sup>, Lucy Wedderburn<sup>6</sup>, Wendy Thomson<sup>1,7</sup>, Kimme Hyrich<sup>1</sup>

<sup>1</sup>Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom; <sup>2</sup>Department of Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom; <sup>3</sup>Department of Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom; <sup>4</sup>Department of Child Health, Glasgow University, Royal Hospital for Sick Children, Glasgow, United Kingdom; <sup>5</sup>Department of Rheumatology, Medical School, Newcastle, United Kingdom; <sup>6</sup>Rheumatology Unit, UCL, Institute of Child Health, London, United Kingdom; <sup>7</sup>NIHR Manchester Musculoskeletal BRU, University of Manchester, Manchester, United Kingdom

**170 MINIMAL DISEASE ACTIVITY IN A CLINICAL COHORT OF CHILDREN WITH JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM THE CHILDHOOD ARTHRITIS PROSPECTIVE STUDY**

Flora McErlane<sup>1,2</sup>, Michael Beresford<sup>1,3</sup>, Eileen Baildam<sup>3</sup>, S. E. Chieng<sup>4</sup>, Joyce Davidson<sup>5</sup>, Helen E. Foster<sup>6</sup>, Janet Gardner-Medwin<sup>5</sup>, Mark Lunt<sup>2</sup>, Lucy Wedderburn<sup>7</sup>, Wendy Thomson<sup>2</sup>, Kimme Hyrich<sup>2</sup>

<sup>1</sup>Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom; <sup>2</sup>Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; <sup>3</sup>Clinical Academic Unit of Paediatric Rheumatology, Alder Hey Children's Hospital, Liverpool, United Kingdom; <sup>4</sup>Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom; <sup>5</sup>Paediatric Rheumatology, University of Glasgow, Glasgow, United Kingdom; <sup>6</sup>Rheumatology, University of Newcastle, Newcastle, United Kingdom; <sup>7</sup>Institute of Child Health, University College London, London, United Kingdom

**171 IDENTIFICATION OF UVEITIS-SPECIFIC AUTOANTIBODIES IN CHILDREN WITH JUVENILE ARTHRITIS: COMPARISON OF THE PLASMA PROFILES OF UVEITIS, NON-UVEITIS AND AGED-MATCHED CONTROLS**

Madeleine Rooney<sup>1</sup>, Sorcha Finnegan<sup>1</sup>, David S. Gibson<sup>1</sup>

<sup>1</sup>Centre for Infection and Immunity, Queens University of Belfast, Belfast, United Kingdom

**172 STANDARDS OF CARE FOR JUVENILE IDIOPATHIC ARTHRITIS: AUDIT ACROSS THE EAST OF ENGLAND PAEDIATRIC RHEUMATOLOGY NETWORK**

Frances A. Borg<sup>1</sup>, Peter J. Bale<sup>2</sup>, Kate Armon<sup>3</sup>

<sup>1</sup>Rheumatology, Southend Hospital, Southend, United Kingdom; <sup>2</sup>Paediatrics, Ipswich Hospital, Ipswich, United Kingdom; <sup>3</sup>Paediatric Rheumatology, Norfolk and Norwich Hospital, Norwich, United Kingdom

**173 HAS THE GAP BEEN BRIDGED YET? CURRENT STATUS OF ADOLESCENT RHEUMATOLOGY SERVICES IN THE UK**

Amparo Cavelle<sup>1</sup>, Helen E. Foster<sup>2</sup>, Janet McDonagh<sup>3</sup>

<sup>1</sup>Paediatric and Adolescent Rheumatology, Birmingham Children's Hospital, Birmingham, United Kingdom; <sup>2</sup>Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom; <sup>3</sup>Immunity and Infection, University of Birmingham, Birmingham, United Kingdom

**174 PATIENTS AND PARENTS VIEWS ON THE ARMA/BSPAR 2010 STANDARDS OF CARE AND ACCESSING TERTIARY LEVEL CARE**

Peter J. Bale<sup>1</sup>, Kate Armon<sup>2</sup>

<sup>1</sup>Paediatrics, Ipswich Hospital, Ipswich, United Kingdom; <sup>2</sup>Paediatric Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom



**Medical student bursary winner**

**175 T-CELL-DEPLETED AUTOLOGOUS STEM CELL TRANSPLANTATION RESULTS IN A CHIMERA OF CLONES FROM BEFORE AND AFTER TRANSPLANT IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS**

Qiong Wu<sup>1</sup>, Anne M. Pesenacker<sup>1</sup>, Alka Stansfield<sup>2</sup>, Douglas King<sup>3</sup>, Dawn Barge<sup>4</sup>, Mario Abinun<sup>4,5</sup>, Helen E. Foster<sup>5</sup>, Lucy Wedderburn<sup>1</sup>

<sup>1</sup>Rheumatology Unit, Institute of Child Health, University College, London, United Kingdom; <sup>2</sup>Scientific Research Laboratory, Cell Medica, London, United Kingdom; <sup>3</sup>Division of Infection and Immunity, Department of Immunology, University College, London, United Kingdom; <sup>4</sup>Department of Paediatric Immunology, Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom; <sup>5</sup>Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom

**PAIN**

**176 WHAT DO PATIENTS REFERRED TO PHYSIOTHERAPY FOR CHRONIC KNEE PAIN BELIEVE, EXPERIENCE AND EXPECT ABOUT EXERCISE AND PHYSICAL ACTIVITY?**

Karen Stanley<sup>1</sup>, Dylan Morrissey<sup>1</sup>, Suzanne Parsons<sup>2</sup>

<sup>1</sup>Sports and Exercise Medicine, Barts and the London, London, United Kingdom; <sup>2</sup>Qualitative Research, Imperial College London, London, United Kingdom

**177 CHRONIC PAIN IN RA: IS IT MEDIATED BY CORTICAL REORGANISATION?**

Anoop Kuttikat<sup>1</sup>, Nicholas Shenker<sup>1</sup>

<sup>1</sup>Rheumatology, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom

**178 CLASSIFICATION CRITERIA FOR FIBROMYALGIA HAVE LIMITED SENSITIVITY IN PATIENTS REFERRED TO A MULTIDISCIPLINARY CLINIC**

Toby Garrood<sup>1</sup>, Sarah Medley<sup>1</sup>, Anna M. Ferguson<sup>1</sup>, Diana Keeling<sup>1</sup>, Patience Duffort<sup>1</sup>, Katherine Irving<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

**179 BODY WEIGHT IS A STRONGER PREDICTOR OF KNEE PAIN THAN BODY COMPOSITION**

Lyndsey Goulston<sup>1</sup>, David Culliford<sup>1</sup>, Patsy Coakley<sup>1</sup>, Pat Taylor<sup>1</sup>, Deborah Hart<sup>2</sup>, Tim Spector<sup>2</sup>, Alan Hakim<sup>3</sup>, Nigel Arden<sup>4</sup>

<sup>1</sup>Faculty of Medicine, University of Southampton, Southampton, United Kingdom; <sup>2</sup>Department of Twin Research, King's College London, London, United Kingdom; <sup>3</sup>Department of Rheumatology, Whipps Cross Hospital, Barts Health NHS Trust, London, United Kingdom; <sup>4</sup>NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, United Kingdom



**180 TREATMENT OF FIBROMYALGIA WITH AMITRIPTYLINE, DULOXETINE, PREGABALIN AND MILNACIPRAN WITH PAIN AS AN OUTCOME MEASURE: A SYSTEMATIC REVIEW AND META-ANALYSIS**

Aneela Mian<sup>1</sup>, Toby Garrood<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

**181 WHAT IS THE BEST MEASURE OF PAIN IN THE ARTHRITIS CLINIC?**

Tejal Magan<sup>1</sup>, Mohsin Chaudhary<sup>1</sup>, Stefan Lazic<sup>1</sup>, Nidhi Sofat<sup>1</sup>

<sup>1</sup>St George's, University of London, London, United Kingdom

**PRIMARY CARE**

**182 "SOMEBODY TO SAY 'COME ON, WE CAN SORT THIS'": A QUALITATIVE STUDY OF HEALTH-SEEKING IN OLDER ADULTS WITH SYMPTOMATIC FOOT OSTEOARTHRITIS**

Martin J. Thomas<sup>1</sup>, Andrew Moore<sup>1</sup>, Edward Roddy<sup>1</sup>, George Peat<sup>1</sup>

<sup>1</sup>Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom

**183 WIDESPREAD VARIATION IN METHOTREXATE SHARED CARE PROTOCOLS: IS A UNIFORM NATIONAL PROTOCOL NEEDED?**

Frances Rees<sup>1</sup>, Peter Lanyon<sup>1</sup>

<sup>1</sup>Rheumatology Department, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

**SLE AND ANTIPHOSPHOLIPID SYNDROME**

**184 MAJOR BLEEDING COMPLICATIONS FOLLOWING PERCUTANEOUS RENAL BIOPSY IN LUPUS NEPHRITIS PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES**

Natasha Jordan<sup>1</sup>, Ahlem Chaib<sup>1</sup>, Shirish Sangle<sup>1</sup>, Fahim Tunjekar<sup>2</sup>, Tarun Sabharwal<sup>3</sup>, Ian Abbs<sup>1</sup>, Munther Khamashta<sup>1</sup>, David D'Cruz<sup>1</sup>

<sup>1</sup>Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom; <sup>2</sup>Department of Renal Histopathology, St Thomas' Hospital, London, United Kingdom; <sup>3</sup>Department of Radiology, St Thomas' Hospital, London, United Kingdom



**185 LONG TERM USE OF MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS - IS IT EFFECTIVE, IS IT SAFE?**

Ida Dzifa Dey<sup>1,2</sup>, David A. Isenberg<sup>1</sup>

<sup>1</sup>Division of Rheumatology, Department of Medicine, University College London Hospitals, London, United Kingdom; <sup>2</sup>Department of Medicine and Therapeutics, Korle Bu Teaching Hospital, Accra, Ghana

**186 ASSOCIATION BETWEEN RETINAL ARTERIOLAR CALIBER AND ENDOTHELIAL DYSFUNCTION IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

Calvin W. Chin<sup>1</sup>, Carol Cheung<sup>2</sup>, Marie Ng<sup>1</sup>, Fei Gao<sup>1</sup>, Fei Qiong Huang<sup>1</sup>, Thu Thao Le<sup>1</sup>, Kok Yong Fong<sup>3</sup>, Ru San Tan<sup>1</sup>, Tien Yin Wong<sup>2</sup>, Thumboo Julian<sup>3</sup>

<sup>1</sup>Cardiovascular Medicine, National Heart Centre Singapore, Singapore, Singapore; <sup>2</sup>Ocular Imaging, Singapore Eye Research Institute, Singapore, Singapore; <sup>3</sup>Department of Rheumatology, Singapore General Hospital, Singapore, Singapore



**187 SUPPRESSION OF INFLAMMATION REDUCES ENDOTHELIAL MICROPARTICLES IN ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS**

Benjamin Parker<sup>1</sup>, Awal Al-Husain<sup>1</sup>, M. Yvonne Alexander<sup>2</sup>, Ian Bruce<sup>1,3</sup>

<sup>1</sup>Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; <sup>2</sup>Institute for Cardiovascular Science, University of Manchester, Manchester, United Kingdom; <sup>3</sup>NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom



**188 LUPUS NEPHRITIS FLARES PRECIPITATED BY SWITCHING FROM MYCOPHENOLATE MOFETIL TO AZATHIOPRINE IN PRE-PREGNANCY PLANNING**

Natasha Jordan<sup>1</sup>, Ian Abbs<sup>1</sup>, David D'Cruz<sup>1</sup>

<sup>1</sup>Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom





**189 TARGETING GLYCOSPHINGOLIPID BIOSYNTHESIS PATHWAYS RESTORES T-CELL FUNCTION IN PATIENTS WITH SLE**

Georgia McDonald<sup>1</sup>, Laura Miguel<sup>1</sup>, Cleo Hall<sup>1</sup>, David A. Isenberg<sup>1</sup>, Anthony Magee<sup>2</sup>, Terry Butters<sup>3</sup>, Elizabeth Jury<sup>1</sup>

<sup>1</sup>Rheumatology, University College London, London, United Kingdom; <sup>2</sup>Molecular Medicine, Imperial College London, London, United Kingdom; <sup>3</sup>Oxford Glycobiology Institute, University of Oxford, Oxford, United Kingdom

**190 PREDICTORS FOR DAMAGE IN A LARGE LONG-TERM PROSPECTIVE COHORT OF SLE PATIENTS**

Chee-Seng Yee<sup>1,2</sup>, Veronica Toescu<sup>2</sup>, Richard Hickman<sup>2</sup>, M. H. Leung<sup>2</sup>, Deva Situnayake<sup>3</sup>, Simon Bowman<sup>4</sup>, Caroline Gordon<sup>2,3</sup>

<sup>1</sup>Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom; <sup>2</sup>Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom; <sup>3</sup>Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom; <sup>4</sup>Department of Rheumatology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

**191 MORTALITY AND DEVELOPMENT OF DAMAGE IN A LARGE PROSPECTIVE COHORT OF SLE PATIENTS**

Chee-Seng Yee<sup>1,2</sup>, Veronica Toescu<sup>2</sup>, Richard Hickman<sup>2</sup>, M. H. Leung<sup>2</sup>, Deva Situnayake<sup>3</sup>, Simon Bowman<sup>4</sup>, Caroline Gordon<sup>2,3</sup>

<sup>1</sup>Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom; <sup>2</sup>Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom; <sup>3</sup>Department of Rheumatology, Sandwell and West Birmingham NHS Trust, Birmingham, United Kingdom; <sup>4</sup>Department of Rheumatology, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom

**192 MEMORY T-CELL SUBSETS PREDICT THE RATE OF B-CELL REPOPULATION FOLLOWING RITUXIMAB THERAPY IN SLE**

Mark N. Lazarus<sup>1</sup>, David A. Isenberg<sup>1</sup>, Michael Ehrenstein<sup>1</sup>

<sup>1</sup>Centre for Rheumatology Research, University College London, London, United Kingdom

**193 ELEVATED SERUM B-CELL ACTIVATING FACTOR CHARACTERISES DISEASE RELAPSE FOLLOWING RITUXIMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS**

Lucy M. Carter<sup>1</sup>, David A. Isenberg<sup>1</sup>, Michael R. Ehrenstein<sup>1</sup>

<sup>1</sup>Centre for Rheumatology, University College London, London, United Kingdom

**194 ROLE OF SEROLOGICAL MARKERS AT BASELINE AND FOLLOW-UP IN PREDICTING BIOPSY PROVEN LUPUS NEPHRITIS**

Neil Chanchlani<sup>1,2</sup>, Mary Gayed<sup>1,2</sup>, Chee-Seng Yee<sup>1,2</sup>, Caroline Gordon<sup>1,2</sup>

<sup>1</sup>Immunity and Infection, University of Birmingham, Birmingham, United Kingdom; <sup>2</sup>Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom

**195 'RHUPUS': AN ULTRASONOGRAPHIC PERSPECTIVE**

Elisabeth Ball<sup>1</sup>, Madeleine Rooney<sup>1</sup>, Aubrey Bell<sup>1</sup>

<sup>1</sup>Department of Rheumatology, Queen's University Belfast, Belfast, United Kingdom

**196 INTERFERON-ALPHA MAY IMPAIR ENDOTHELIAL REPAIR MECHANISMS IN SYSTEMIC LUPUS ERYTHEMATOSUS**

John A. Reynolds<sup>1,2</sup>, David W. Ray<sup>3</sup>, Terence O'Neill<sup>1</sup>, Yvonne Alexander<sup>4</sup>, Ian Bruce<sup>1,2</sup>

<sup>1</sup>Arthritis Research UK Epidemiology Unit, Institute of Inflammation and Repair, University of Manchester, Manchester, United Kingdom; <sup>2</sup>NIHR Manchester Musculoskeletal BRU, University of Manchester, Manchester, United Kingdom; <sup>3</sup>Endocrine Sciences Research Group, University of Manchester, Manchester, United Kingdom; <sup>4</sup>Cardiovascular Research Group, University of Manchester, Manchester, United Kingdom

**197 CHARACTERISTICS OF PATIENTS WITH REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS REQUIRING BIOLOGIC THERAPY IN A UK MULTICENTRE COHORT**



Emily J. Sutton<sup>1</sup>, Kath D. Watson<sup>1</sup>, David Isenberg<sup>2</sup>, Anisur Rahman<sup>2</sup>, Caroline Gordon<sup>3</sup>, Chee-Seng Yee<sup>4</sup>, Peter Lanyon<sup>5</sup>, David Jayne<sup>6</sup>, Mohammed Akil<sup>7</sup>, David D'Cruz<sup>8</sup>, Munther Khamashta<sup>8</sup>, Pamela Lutalo<sup>8</sup>, Nicola Erb<sup>9</sup>, Athiveer Prabu<sup>10</sup>, Chris J. Edwards<sup>11</sup>, Hazem Youssef<sup>12</sup>, Neil McHugh<sup>13</sup>, E. Vital<sup>14</sup>, Nicole Amft<sup>15</sup>, Bridget Griffiths<sup>16</sup>, Lee-Suan Teh<sup>17</sup>, Asad Zoma<sup>18</sup>, Ian Bruce<sup>1</sup>

<sup>1</sup>Arthritis Research UK Epidemiology Unit, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom; <sup>2</sup>Centre for Rheumatology, University College London, London, United Kingdom; <sup>3</sup>Rheumatology Research Group, University of Birmingham, Birmingham, United Kingdom; <sup>4</sup>Department of Rheumatology, Doncaster and Bassetlaw Hospitals NHS Foundation Trust, Doncaster, United Kingdom; <sup>5</sup>Rheumatology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom; <sup>6</sup>Department of Nephrology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom; <sup>7</sup>Department of Rheumatology, Sheffield Teaching Hospitals NHS Trust, Sheffield, United Kingdom; <sup>8</sup>Lupus Research Unit, St Thomas' Hospital, London, United Kingdom; <sup>9</sup>Rheumatology Department, The Dudley Group NHS Foundation Trust, Dudley, United Kingdom; <sup>10</sup>Department of Rheumatology, Worcestershire Acute Hospitals NHS Trust, Worcester, United Kingdom; <sup>11</sup>Department of Rheumatology, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom; <sup>12</sup>Department of Rheumatology, NHS Grampian, Aberdeen, United Kingdom; <sup>13</sup>Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom; <sup>14</sup>Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom; <sup>15</sup>Rheumatic Diseases Unit, NHS Lothian, Edinburgh, United Kingdom; <sup>16</sup>Rheumatology, The Newcastle Hospitals NHS Foundation Trust, Newcastle, United Kingdom; <sup>17</sup>Department of Rheumatology, East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom; <sup>18</sup>Rheumatology, NHS Lanarkshire, East Kilbride, United Kingdom

**198 HIGH PREVALENCE OF A POSITIVE FAMILY HISTORY OF SYSTEMIC LUPUS ERYTHEMATOSUS IN JUVENILE-ONSET VERSUS ADULT-ONSET DISEASE: A COMPARATIVE STUDY**

Maurer Durrani<sup>1</sup>, Natasha Jordan<sup>1</sup>, Shirish Sangle<sup>1</sup>, David D'Cruz<sup>1</sup>

<sup>1</sup>Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom

**199 AFFINITY-PURIFIED ANTIBODIES DIRECTED TO DOMAIN I OF 2GPI ARE PATHOGENIC IN A MOUSE MODEL OF THROMBOSIS**



Charis Pericleous<sup>1</sup>, Patricia Ruiz-Limon<sup>2</sup>, Zurina Romy-Penabad<sup>2</sup>, Ana Carrera-Marin<sup>2</sup>, Acely Garza-Garcia<sup>3</sup>, Lucy Murfitt<sup>3</sup>, Paul C. Driscoll<sup>3</sup>, Ian P. Giles<sup>1</sup>, Yiannis Ioannou<sup>1</sup>, Anisur Rahman<sup>1</sup>, Silvia S. Pierangeli<sup>2</sup>

<sup>1</sup>Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom; <sup>2</sup>Experimental Rheumatology, University of Texas Medical Branch, Galveston, TX, USA; <sup>3</sup>Structural Biology, MRC National Institute of Medical Research, London, United Kingdom

**200 UNRAVELLING MONOCYTE RESPONSES TO ANTIPHOSPHOLIPID ANTIBODIES**

Vera M. Ripoll<sup>1</sup>, Anastasia Lambrianides<sup>1</sup>, Wendy E. Heywood<sup>2</sup>, John Ioannou<sup>1</sup>, Ian P. Giles<sup>1</sup>, Anisur Rahman<sup>1</sup>

<sup>1</sup>Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom; <sup>2</sup>Institute of Child Health, University College London, London, United Kingdom

**201 THE IMPACT OF NON-VISIBLE SYMPTOMS IN SYSTEMIC LUPUS ERYTHEMATOSUS**

Claire Stevens<sup>1</sup>, Emma Dures<sup>1,2</sup>, Marianne Morris<sup>2</sup>, Shari Knowles<sup>2</sup>, Sarah Hewlett<sup>2</sup>, Robert Marshall<sup>2</sup>

<sup>1</sup>Psychology, UWE, Bristol, United Kingdom; <sup>2</sup>Rheumatology, Bristol Royal Infirmary, Bristol, United Kingdom

**202 SERUM RITUXIMAB LEVELS AND EFFICIENCY OF B-CELL DEPLETION: DIFFERENCES BETWEEN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND RHEUMATOID ARTHRITIS**

Venkat Reddy<sup>1</sup>, Sara Croca<sup>1</sup>, Delia Gerona<sup>2</sup>, Inmaculada De La Torre Ortega<sup>2</sup>, David A. Isenberg<sup>1</sup>, Maria Leandro<sup>1</sup>, Geraldine Cambridge<sup>1</sup>

<sup>1</sup>Rheumatology, University College London, London, United Kingdom; <sup>2</sup>Rheumatology, Gregorio Marañon Hospital, Madrid, Spain

**203 USE OF AN IN VITRO WHOLE-BLOOD DEPLETION ASSAY TO COMPARE THE EFFICACY OF B-CELL DEPLETING AGENTS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

Venkat Reddy<sup>1</sup>, Geraldine Cambridge<sup>1</sup>, David A. Isenberg<sup>1</sup>, Martin Glennie<sup>2</sup>, Mark Cragg<sup>2</sup>, Maria Leandro<sup>1</sup>

<sup>1</sup>Rheumatology, University College London, London, United Kingdom; <sup>2</sup>Tenovus Cancer Research Centre, Southampton University Hospital, Southampton, United Kingdom

**204 ANTI-NUCLEOSOME ANTIBODIES ARE ASSOCIATED WITH DISEASE ACTIVITY AND HYDROXYCHLOROQUINE USE IN PATIENTS WITH SLE: A LONGITUDINAL, MULTIVARIATE ANALYSIS OF 398 SAMPLES**

Sara C. Croca<sup>1</sup>, David A. Isenberg<sup>1</sup>, Ian Giles<sup>1</sup>, Yiannis Ioannou<sup>1</sup>, Anisur Rahman<sup>1</sup>

<sup>1</sup>Rheumatology, University College London, London, United Kingdom

**205 ANTI-APOA1 ANTIBODIES ASSOCIATE WITH DISEASE ACTIVITY IN LUPUS AND ARE LOWER IN PATIENTS TAKING HYDROXYCHLOROQUINE: A LONGITUDINAL ANALYSIS OF 398 SAMPLES**

Sara C. Croca<sup>1</sup>, David A. Isenberg<sup>1</sup>, Ian Giles<sup>1</sup>, Yiannis Ioannou<sup>1</sup>, Anisur Rahman<sup>1</sup>

<sup>1</sup>Rheumatology, University College London, London, United Kingdom

**206 ANTI-FACTOR Xa ANTIBODIES ARE SIGNIFICANTLY INCREASED IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND ANTIPHOSPHOLIPID SYNDROME**

Bahar Artim Esen<sup>1</sup>, Charis Pericleous<sup>1</sup>, Ian MacKie<sup>2</sup>, Yiannis Ioannou<sup>1</sup>, Anisur Rahman<sup>1</sup>, David A. Isenberg<sup>1</sup>, Ian Giles<sup>1</sup>

<sup>1</sup>Center for Rheumatology, Division of Medicine, University College London, London, United Kingdom; <sup>2</sup>Haemostasis Research Unit, Department of Haematology, University College London, London, United Kingdom

**207 CELLULAR ADHESION MOLECULES AS POTENTIAL BIOMARKERS OF NEPHRITIS, DAMAGE AND ACCELERATED ATHEROSCLEROSIS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS**

Sarah Skeoch<sup>1</sup>, Sahena Haque<sup>2</sup>, Philip Pemberton<sup>3</sup>, Ian Bruce<sup>1</sup>

<sup>1</sup>Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom; <sup>2</sup>Department of Rheumatology, East Lancashire Hospitals NHS Trust, Blackburn, United Kingdom; <sup>3</sup>Clinical Research Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom